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ABSTRACT
CHARACTERIZATION OF BIODISTRIBUTION OF TRANSFERRIN AND RECEPTOR BINDING
MECHANISM BY MASS SPECTROMETRY
FEBRUARY 2020
HANWEI ZHAO, B.S., CAPITAL MEDICAL UNIVERSITY, CHINA
M.S., UNIVERSITY OF MASSACHUSETTS LOWELL
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Igor A. Kaltashov
Protein‐based therapeutics have emerged as a key driver of rapid growth in drug
development pipelines. However, developing such protein drugs is not straightforward
in most cases, the existence of physiological barriers greatly restricts the efficient
delivery of many therapeutic molecules, and therefore limits their clinical applications. A
promising way to address this challenge takes advantage of certain transport protein
which can effectively across and enhance the permeability of these barriers, such as
transferrin (Tf) which can be internalized by malignant cells and cross physiological
barriers via transferrin receptor (TfR)‐mediated endocytosis and transcytosis. However,
developing such products is impossible without successfully understanding the
molecular mechanisms governing Tf/TfR interactions and the ability to monitor the
biodistribution of Tf. In this work, hydrogen/deuterium exchange mass spectrometry
(HDX MS) is used to investigate TfR higher order structural and dynamic changes in
different Tf/TfR models that mimic various stages encountered during endocytosis.
Detailed characterizations of TfR gained by HDX MS reveal the regions located at the
vii

interdomain cleft exhibiting bimodal exchange patterns may be responsible for the loss
of its enzyme function in the molecular evolution. At neutral pH, a movement at the
TfR/TfR interface helps to stabilize the holoTf/TfR complexation. At acidic pH, the pH‐
induced conformational changes at the TfR helical domain trigger a series of movements
that lead to specific binding properties for holo‐ and apoTf C‐lobe. Obtaining this
information greatly enhances our understanding of the pH‐dependent Tf binding
properties and how TfR facilitates iron release at acidic pH. Another aspect of this
dissertation work is utilizing the ability of Tf to bind to noncognate metals to trace the
biodistribution of Tf. Particularly, indium has been evaluated and demonstrated as an
ideal tracer of exogenous Tf in complex biological matrices using inductively coupled
plasma mass spectrometry (ICP MS) as a detection tool. In addition, combining laser
ablation (LA) with ICP MS detection allows distribution of exogenous Tf to be mapped
within animal tissue cross‐sections. The high sensitivity and selectivity of this novel
approach make it an ideal quantitation/imaging tool for in vivo studies of biodistribution
of Tf and Tf‐based therapeutics.
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INTRODUCTION
Transferrin‐Based Drug Delivery and Transferrin/Transferrin Receptor System
Protein Drugs and Drug Delivery
Since the introduction of the first recombinant protein therapeutics, human
insulin (1), protein drugs have emerged as an important class on the pharmaceutical
market serving patients most in need of novel therapies, including monoclonal
antibodies as well as large or fusion proteins. Protein drugs generally have high
molecular weights, complex secondary and tertiary structures and post‐translational
modifications. Due to the complexity of protein drugs, they are engineered to be more
specific with the molecular target and have enhanced potency and functionality as well
as fewer site‐effects. Understanding the protein structure/function and the mechanism
of action leads to the customization of existing proteins or the development of next‐
generation biological therapeutics strategies for specific clinical use. The recent US‐FDA
approved therapeutic proteins have been developed to treat a wide variety of
therapeutic

areas,

including

metabolic/hormonal

disorders,

cancers,

hematology/oncology, cardiology/vascular diseases, autoimmunity, genetic disorders,
and infectious disease (2,3).
While the protein drugs have developed significantly in the past decades, the
inability for efficient and accurate delivery has limited their use. Despite significant
investments and extensive R&D efforts, there are several challenges that make the
development of biopharmaceuticals slow down, such as the presence of the scavenger
1

proteins and various filters (glomerular filter) and barriers (enzymatic barrier and
physiological barriers) in the body. A common problem encountered in these areas is
the inability of most proteins to cross physiological barriers, such as the gastrointestinal
epithelial barrier and the blood‐brain barrier (BBB) which restrict the development of
protein drugs for oral administration and targeting pathologies in the central nervous
system (CNS), respectively.
A receptor‐mediated delivery system is one of the attractive strategies to
overcome the limitation in drug absorption that enable the endocytosis/transcytosis of
the proteins across physiological barriers in the body. This provides a promising
approach for the treatment of brain diseases and the development of a viable
mechanism of oral delivery. Examples of transported substances to CNS via receptor‐
mediated transcytosis include insulin (4), transferrin (Tf) (5), leptin (6), and the low‐
density lipoprotein receptor‐related protein (LRP) (7). These proteins can be utilized as
drug delivery vehicles, and the therapeutic protein can be tethered to them as payload
by either conjugation (chemical cross‐linking) or expression as a recombinant fusion
protein. It is clear that the successful implementation of this route in drug delivery
strategies needs a better understanding of the interactions between the receptors and
protein‐based therapeutics. In this dissertation, we focus on evaluating the molecular
mechanisms of Tf and transferrin receptor (TfR) system.
The Role of Tf/TfR System in Drug Delivery

2

Tf is a very promising target for a growing number of therapeutic strategies for
the purpose of devising highly efficient and selective drug delivery systems, as indicated
by numerous reviews (8‐10), due to its ability to enter the cell or cross physiological
barriers in the process of TfR‐mediated endocytosis or transcytosis (Figure 1‐1). TfR
performs as a cellular iron homeostasis adjustor: the low iron concentrations inside the
cell increase the level of TfR expression by increasing the half‐life of the TfR message
translation in order to increase the iron intake into the cell. Therefore, the level of the
soluble form of TfR can be used to monitor erythropoiesis (11). Besides this, TfR
appears to be ubiquitously expressed in almost all nucleated cells, for example, red
blood cells, thyroid cells, hepatocytes, brain, intestinal cells, and monocytes (12), but is
overexpressed in various types of cancer cells, such as immature erythroid cells,
placental tissue, and rapidly dividing cells, due to their high rates of proliferation and
increased demand for iron (8,13‐15). As a result of its differential expression in normal
and malignant tissues, TfR has been investigated as a target for pharmacological
intervention for several decades (16) and TfR‐mediated pathway has also been explored
for efficient therapeutic molecules and protein delivery (17‐19).
A wide range of therapeutic agents (such as chemotherapeutic drugs, protein
toxins, radionuclides, DNA, modified viral particles, and nanoparticles) can be tethered
to Tf and delivered to malignant cells by targeting TfR on the cell surface (8,10). The
therapeutic efficacy of drug delivery via TfR‐mediated pathway can be enhanced due to
more effective tumor targeting and less nonspecific toxicity. For example, the cisplatin‐
Tf conjugate, MPTC‐63, which has already entered the clinical trials showed an anti‐
3

tumor response in human epidermoid cancer with minor side effects (20). Another
example for Tf‐conjugates is MBP‐426, a liposome‐Tf conjugate for the delivery of
oxaliplatin, which is in a Phase II clinical trial for patients with gastric, gastroesophageal,
or esophageal adenocarcinoma (8). Normally, the receptor‐mediated endocytosis is a
saturable process, because of the limited number of the receptors on the cell surface.
The nonlinear pharmacokinetics of the recombinant human erythropoietin (rh‐EPO) (21)
can be used to support this. This trait may limit the dose and efficacy of the drugs, but
on the other hand, it can be used to reduce the drug clearance by inhibiting certain
receptor‐mediated endocytosis (22).
In addition, Tf is often considered as a promising metal‐based drug delivery
vehicle (10,23). Metal ions are fundamental components of cells and have been
frequently incorporated into pharmaceuticals for therapeutic or diagnostic purposes.
However, due to the severe side effects and the unstable ionic states of certain metal
ions, many metals are investigated for improved pharmacological profiles. In the serum
of healthy human subjects, only approximately 30% of Tf is saturated with iron (24),
which provides a potential ability for the protein to bind and transport other metal ions
from blood to tissues. Indeed, Tf can also bind with a wide range of other metals ions
due to their biochemical similarities with iron and serve as a noniron metal mediator.
This extends its function to deliver certain metals, including essential elements other
than iron (e.g., Mn), therapeutic metal ions (e.g., Bi3+, Ru3+ and Ti4+), radio diagnostic
metal ions (e.g., 67Ga3+ and 111In3+), and some toxic metal ions (e.g., Th4+ and U6+), with
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various affinities (25‐27). Importantly, many of these metal‐Tf complexes can still be
recognized by TfR (26).
Since TfR is also overexpressed in the brain capillaries, TfR‐mediated transcytosis
(Figure 1‐1B) has been focused as one of the most efficient pathways for the delivery of
therapeutic molecules to CNS. Briefly, Tf binds to TfR on the apical membrane.
Subsequently, the membrane invaginates to form an intracellular vesicle through
endocytosis. The vesicle migrates across the cytoplasm and fuses with the
basolateral membrane. Then Tf is released from the receptor on the abluminal surface.
Although a detailed understanding of cellular mechanisms associated with TfR‐mediated
uptake pathway at the BBB remains unclear, several studies have demonstrated the
ability of TfR to deliver Tf‐drug conjugates (9,28) and TfR‐antibody conjugates (29,30)
into the brain. The former is achieved either by chemical conjugation of therapeutic
drugs, proteins with Tf or by genetic infusion of therapeutic peptides or proteins into
the structure of Tf; while the latter is using engineered anti‐TfR antibodies as artificial
ligands which can be used to shuttle therapeutic molecules into the brain. Furthermore,
in addition to mediating transcytosis across BBB in blood‐to‐brain direction, TfR can also
mediate reverse transcytosis of Tf in brain‐to‐blood direction, as the evidence of the
efflux of both apo‐ and holoTf across BBB (31). Numerous efforts aiming at utilizing this
unique trait for the purpose of targeted drug delivery that ranges from small molecules
to macromolecular drugs and supramolecular assemblies (32,33) are underway, with the
ultimate goal of developing therapeutic agents that can reach targets shielded from the
vast majority of existing drugs. Contributing to this goal, our group has started exploring
5

a possibility of conjugating a bacteriolytic enzyme, lysozyme, to Tf for targeting
microbial infections in the central nervous system (34,35).

Figure 1‐1 Schematic diagram of (A) TfR‐mediated endocytosis and (B) transcytosis for
Tf‐based therapeutic delivery to intracellular targets and CNS targets, respectively.
Figure is from Reference (35).
Characterization of TfR‐Mediated Endocytosis
Iron is an essential nutrient that participates in various biological processes.
Mammalian cells utilize multiple mechanisms to acquire inorganic iron. The primary
route for most cells to uptake circulating iron is via Tf/TfR‐mediated endocytosis (Figure
1‐1A), which is negatively modulated by HFE (the hereditary hemochromatosis protein,
which is related to class I major histocompatibility complex proteins (36) and is mutated
in the iron‐overload disease hereditary haemochromatosis) in transfected cells (37,38)
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due to the same or significantly overlapping TfR binding sites for Fe2Tf and HFE. TfR
binds two molecules of Fe2Tf at the cell surface. The initial stage of the binding
mechanism of Fe2Tf to TfR at neutral pH is the loss of protons from TfR at the Tf binding
sites with a proton loss pKa =8 (39). Upon addition of Fe2Tf, an intermediate of Tf/TfR
where the C1‐subdomain of Tf is bound to TfR is formed within microsecond range.
Then this intermediate undergoes a slow change in its conformation bringing to the final
thermodynamic state where both N‐ and C‐lobe of Tf are bound to TfR (39).
The Tf/TfR complex is then internalized through clathrin‐coated pits to form a
vesicle, which buds from the plasma membrane, at the cell surface, and subsequently
transported to endosomes. Protons are pumped into the endosomes through the action
of an ATP‐dependent proton pump resulting in a decrease in pH to about 5.5, which
triggers the conformational change of the complex and the subsequent release of iron
from Tf. The free ferric iron (Fe3+) released to endosomes is reduced to ferrous iron (Fe2+)
by the endosomal metalloreductase STEAP3 (six‐transmembrane epithelial antigen of
the prostate 3) (40) and Fe2+ is subsequently transported out of the endosome into the
cytoplasm by DMT1 (divalent metal transporter 1) (41). By an iron transport molecule,
the cytosolic iron is shuttled to various intracellular locations, including the
mitochondria (for heme and ribonucleotide reductase incorporation) and ferritin (for
storage) (42,43).
After the iron is released from Tf, the resultant apoTf remains bound to TfR with
high affinity. Then the apoTf/TfR complex is quickly recycled back to the cell surface
through exocytic vesicles and apoTf is released into the serum either through
7

dissociation from TfR or displacement by Fe2Tf or monoferric‐Tf (44) due to its weak
receptor binding affinity at neutral pH. The apoTf molecule then circulates until it
couples to free irons, and the cycle is continued. The entire iron uptake cycle lasts only 4
to 5 minutes (45).
TfR’s preference for apoTf at endosomal pH not only facilitates iron release from
Tf, but also saves it from inevitable degradation in the lysosomal compartment after
endocytosis, where most internalized proteins end up unless they keep bound to a
membrane‐associated receptor, and recycles back to the cell surface for recycling. Once
such "recycling" is no longer needed, the protein is serviced by a different receptor. An
example is the lactoferrin (Lf), one of the four distinct members of the transferrin family
in mammals (46). It arose from a duplication of Tf gene in the ancestor of mammals
approximately 160 million years ago (47). Despite its affinity for iron, Lf is not required
for iron homeostasis in the body (48). Instead, it is functioned as part of the innate
immune and catalytic response (49). Unlike Tf, Lf cannot bind to TfR but it binds to a
number of receptors from unrelated protein families, such as low density lipoprotein
receptor‐related protein 1 and 2, which are expressed in the bone, cartilage, fibroblasts
and brain cells (50). In contrast to Tf, iron is released from Lf when a portion of the
endocytosed Lf is routed to the lysosomal compartment and the Lf/receptor complex is
degraded. Of course, TfR is not unique in its "guardian" role: the neonatal Fc receptor
(FcRn) accomplishes a similar task, which rescues phagocytosed IgGs and serum albumin
from being routed to lysosomes (51). However, the structures of the FcRn/IgG and
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FcRn/albumin complexes are very different from that of Tf/TfR, and the mechanism of
pH‐dependent binding is different.
The structures of Tf, TfR and the Tf/TfR Complexes
1.1.4.1

Tf
Human Tf is an 80 kDa monomeric bilobal glycoprotein that transports otherwise

insoluble ferric ions (Fe3+) through the bloodstream to cells and crosses the physiological
barriers via receptor‐mediated endocytosis/transcytosis. Tf has two structurally similar
lobes, generally termed the N‐ and C‐lobe, and each lobe is composed of two
subdomains (N1 (residues 1‐92 and 247‐331), N2 (residues 93‐246), and C1 (residues
339‐425 and 573‐679), C2 (residues 426‐572)), forming an interdomain cleft which
provides a distinct binding site for a ferric ion. It has an extremely high affinity for ferric
ions (Kd is 1023 M−1 at pH 7.4 (52)) and forms holo‐Tf at neutral pH. Fe3+ is held tightly
within one or both homologous N‐ and C‐lobes of Tf (Fe2Tf, FeNTf, and FeCTf). Each lobe
undergoes a significant conformational change upon Fe3+ binding (the two subdomains
in each lobe rotate towards each other by approximately 50°), which results in a closing
of the metal binding cleft (Figure 1‐2). In each lobe the bound ferric ion is coordinated in
a near octahedral geometry, with four ligands provided by the protein (one aspartate
residue, Asp63/392 in N1/C1, one histidine residue, His249/585 in N1/C1, and two
tyrosine residues, Tyr188/517 in N2/C2 and Tyr95/426 in N2/C2) and the two remaining
ligands provided by the synergistic carboxylic anion (carbonate or oxalate) (Figure 1‐3).
The synergistic anion is essential for Tf to facilitate specific and strong ferric ion binding
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(53). In the absence of a synergistic anion, the ferric ion has no affinity for the metal
binding site which results in nonspecific binding and hydrolytic polymerization at the
physiological pH (54). Substitution of carbonate by oxalate anion can effectively lock the
iron into each lobe of Tf which results from a symmetric bidentate interaction with iron
and the low pKa of the oxalate anion (4.2 for oxalate vs 6.4 for carbonate) (55,56).
Although the two lobes are highly homologous (49% homology (57)), their metal‐binding
properties are significantly different. The C‐lobe of the protein has a higher affinity for
ferric ion (58), and the iron release from the C‐lobe of the protein occurs at a more
acidic pH than the N‐lobe (59). The transition from the closed to the open state of Tf
upon mild acidification is due to the protonation of the residues K534, R632, and D634
in the C‐lobe which serves as the pH‐sensitive triad, and the pH‐dependent dilysine
trigger (K206 and K296) in the N‐lobe (60). Mutating any of these residues to the
dysfunctional pH‐sensitive element will effectively lock the lobe in the closed
conformation, even at endosomal pH, by reducing the iron release rates by 2‐4 orders of
magnitude compared to the wild‐type Tf (45,61). The R632A mutation transforms a pH‐
sensitive triad in the C‐lobe to a strong salt‐bridge K534∙∙∙D634 favoring the closed
conformation, while mutating K206 to an acidic residue, glutamic acid, can convert the
dilysine trigger to a very stable salt‐bridge E206∙∙∙K296 and nearly irreversibly lock the N‐
lobe in the closed conformation.
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Figure 1‐2 Crystal structures of the apo‐ (A, PDB: 2HAV) and holo‐form (B, PDB: 3V83) of
human Tf showing the details of iron binding. Side chains coordinating with iron are
shown as blue sticks; both ferric ions and the synergistic anions are shown as spheres
(Fe: red; C: green; and O: brown).

Figure 1‐3 Zoomed‐in view of the Fe3+ binding site of the N‐lobe of Tf (PDB: 1A8E). Side
chains coordinating with iron are shown as stick structures, and Fe3+ is shown as a
brown sphere.
1.1.4.2

TfR
TfR is a homodimeric type II transmembrane glycoprotein on the cell surface. A

full‐length TfR is made up of a short N‐terminal cytoplasmic tail (residues 1‐67) with an
internalization motif (YTRF), a single hydrophobic transmembrane region (residues 68‐
88), and a stalk (residues 89‐120) connected to the Tf binding ectodomain (residues 121‐
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760) (62) (Figure 1‐4A). The stalk contains the trypsin cleavage site which results in the
release of the soluble ectodomain. The ectodomain is a dimer and each TfR monomer
contains three distinct domains (Figure 1‐4B): the protease‐like domain (residues 121‐
188 (PA1) and 384‐606 (PA2)), the apical domain (residues 189‐383), and the helical
domain (residues 607‐760) (63). There are three N‐linked glycosylation sites in TfR
(Asn251, Asn317, and Asn727), while only Asn317 shows a significant effect on TfR
solubility and can stabilize the apoTf bound to TfR at endosomal pH (64).

Figure 1‐4 The structure of TfR. (A) The schematic figure of the full‐length TfR. (B) The
crystal structure of the ectodomain of TfR (PDB: 1CX8). The TfR homodimer is colored
according to the domains: the apical domain is blue, the protease‐like domain is red,
and the two monomers of the helical domain are green and cyan, respectively.
1.1.4.3

The Tf/TfR complexes
As the function of receptor, the soluble ectodomain of TfR can bind two Tf

molecules. Both the N‐lobe and C1‐subdomain of Tf are required for maximal TfR
binding, and the C‐lobe is the primary receptor recognition site and contributes
approximately 60% to the Tf/TfR interface (65). At neutral pH, TfR prefers to bind with
Fe2Tf with the dissociation constant (Kd) at 10‐9 M level (66,67), about 30 times greater
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compared to the dissociation of apoTf/TfR (68,69) and 8‐9 times greater than that with
monoferric‐Tf; while these two monoferric species have similar receptor binding affinity
(67). In contrast, at acidic pH, the affinity of apoTf for TfR is about 7 times higher than
holoTf (70), but about 2‐4 times lower than the holoTf and TfR at neutral pH (66,69,71).
The first publication of the structure of the Tf/TfR complex was a 7.5 Å resolution
cryo‐electron microscopy (EM) model of Fe2Tf/TfR in 2004 (PDB: 1SUV) (Figure 1‐5A)
(72). Due to the lack of the crystal structure of either full‐length human apoTf or Fe2Tf at
that time, this cryo‐EM model was built by docking the crystal structures of the TfR
alone and the isolated N‐lobe of iron‐loaded human Tf and the C‐lobe of rabbit Tf (78%
sequence identity and 92% sequence similarity to the C‐lobe of human Tf (73)) into the
electron density map. This model shows that the N‐lobe of Tf is sandwiched between
the membrane and the TfR and that the C1‐subdomain is contacted with the helical
domain of TfR. Comparison of the structures of the free rabbit Fe2Tf with the docked
model shows a ~9 Å shift between the N‐ and C‐lobe of Tf (Figure 1‐5A). The relatively
low resolution of the EM map provides a rather hazy and ambiguous picture of the
Tf/TfR interaction. After the crystal structure of apoTf became available (74) and
employing the modeled structure using the structures of iron bound human N‐lobe Tf
and diferric hen ovoTf, the computational structure models of apoTf/TfR and Fe2Tf/TfR
complexes were generated by Yamamura group in 2009 (75). These models eliminate
the 9 Å conformational change of Tf upon complexation and are consistent with the
available mutagenesis experiments (66,67). Moreover, these models suggest that the
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residue Arg651 in TfR is a hot spot for Tf/TfR binding, which can interact with the
residue Glu385 in both apoTf and Fe2Tf.
In combination with previous structures of the free TfR, the TfR/HFE complex (76)
and the EM model of Tf/TfR complex, a most recently published crystal structure of the
FeNTf/TfR complex (PDB: 3S9N) at a high resolution of 3.22 Å (Figure 1‐5B) (65) reveals
various aspects of the intramolecular movements in TfR as a result of Tf binding and the
interactions between the N‐lobe and C1‐subdomain of Tf and TfR that allow for the
cellular uptake of Tf and affect iron release from Tf in the presence of TfR. Three
primary interaction motifs are involved here (Figure 1‐5C‐D). 1) The N1 subdomain of Tf
contacts the bottom region of the helical domain of TfR by a salt bridge between Arg50
2) Two loops within the N2 subdomain of Tf, the PRKP loop (residues [142‐145]) and the
loop [154‐167], make contacts with the N‐terminal of TfR. Three residues in the PRKP
loop, Pro142, Lys144, and Pro145, participate in high affinity receptor binding (67). 3)
The C1 subdomain of Tf forms a large interaction surface with the helical domain of TfR
through Tf Asp356‐TfR Arg651 salt bridge, and side chain interactions between a
number of charged Tf residues (Arg352, Glu357, Glu367 and Glu385) and TfR (77).
Although no experimental evidence was provided that the C2 subdomain of Tf is
involved in binding to TfR (65), it may stabilize binding of the iron‐loaded C‐lobe of Tf in
the Tf/TfR complex, as the evidence of mutation of Lys511 in the C2 subdomain, which
does not contact with TfR, can affect the receptor binding (32). Additionally,
conformational changes at the TfR dimer interface that induced by Tf binding, priming
TfR to undergo pH‐induced movements that affect the Tf/TfR binding. The mechanisms
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of iron release from each lobe of Tf in the presence of TfR are different: binding of
His349 to TfR is critical for stimulating iron release from the C lobe, whereas binding
with TfR may limit access to a kinetically significant anion binding site in the N2
subdomain (78) that hinders iron release from the N lobe.
Although this high‐resolution crystal structure of the FeNTf/TfR complex allows a
more accurate description of the specific interactions between the two binding partners
at neutral pH, it remains hypothetical how the internal motions relate to changes of TfR
binding preferences throughout endocytosis. Understanding of the Tf/TfR pathway
could further allow us to understand molecular mechanisms governing Tf/TfR
interaction and garner important knowledge needed for the rational design of Tf
conjugates in drug delivery strategies to maximize the use of this system.
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Figure 1‐5 The structures of Tf/TfR complexes. (A) The overlay structures of the cryo‐EM
model of Fe2Tf/TfR (PDB: 1SUV) and the rabbit Fe2Tf (yellow, PDB: 1JNF), showing the ~9
Å shift between the N‐ and C‐lobe of Tf. (B) The crystal structure of FeNTf/TfR complex
(PDB: 3S9N). The primary interaction motifs of Tf N‐lobe/TfR and Tf C1/TfR in FeNTf/TfR
complex (PDB: 3S9N) are shown in panel (C) and (D), respectively. The TfR homodimer is
colored according to the domains: the apical domain is blue, the protease‐like domain is
red, and the two monomers of the helical domain are green and cyan, respectively. The
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N‐ and C‐lobe of Tf molecule in Fe2Tf/TfR in panel (A) are colored in white and magenta,
respectively. The FeNTf molecules in panels (B), (C) and (D) are colored according to
subdomains: N1 is gray, N2 is black, and C1 is magenta. The Fe3+ bound to each N‐lobe
of Tf in panel (B) is shown as the orange dot.
TfR and its Homologous Proteins
There are at least seven different homologous proteins in the TfR family in
primates, including TfR1, TfR2, glutamate carboxypeptidase II or prostate‐specific
membrane antigen (GCP2 or PSMA), N‐acetylated α‐linked acidic dipeptidase‐like
protein (NAALADase), N‐acetylated α‐linked acidic dipeptidase 2 (NAALAD2), prostate‐
specific membrane antigen‐like protein or glutamate carboxypeptidase III (PSMAL or
GCPIII), and N‐acetylated α‐linked acidic dipeptidase‐like protein 2 (NAALADase2). In
general, the TfR family members can be divided into two subfamilies based on their
functions: receptors and enzymes. However, of these homologs, only hTfR1, hPSMA and
NAALADase have the published structures so far and the functions of some members
remain uncertain (79). TfR2 is also a receptor protein, which is expressed in the liver and
erythroid cells, participating in modulating hepcidin expression. Mutations to TfR2 result
in type 3 hemochromatosis (80). It has 66% similarity to the extracellular domain of TfR1,
but 30% lower binding affinity for Tf (81). The differences in the helical domain between
the two TfRs, as well as the C‐terminus, together with the apical domain arm junction
(residue 306‐330 in TfR1) account for the different Tf binding rates (82). Other than TfR,
the best‐studied member in this family is PSMA which is primarily functioned as an
enzyme. It is weakly expressed in normal prostate tissue, but the amount is markedly
increased in prostate cancer cells due to the regulation of androgen (83). In addition,
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PSMA is also highly expressed in other cancers, more specifically in the tumor‐
associated neovasculature (84). Therefore, it has been used as a prostate cancer cell‐
surface biomarker and a target for imaging the neovasculature of tumors. PSMA acts as
a glutamate carboxypeptidase with two separate catalytic functions: folate hydrolase (in
the proximal renal tubules and duodenum) and NAALDase (in the brain), resulting in the
release of glutamate from the enzyme substrates (85,86).
A structure‐based alignment of TfR1 and PSMA reveals certain common features:
a short N‐terminal cytoplasmic tail, a single hydrophobic transmembrane domain, and a
large extracellular domain (Figure 1‐4A) (79). A novel MXXXL motif in the cytoplasmic
tail in PSMA mediates its internalization via clathrin‐dependent endocytosis (87). As
shown in Figure 1‐6, the extracellular domain of both proteins has three structurally
diverse domains: an apical domain, a protease or protease‐like domain, and a helical
domain. The extracellular domain of PSMA shows structural homology to TfR1 (26%
sequence identity, 46% similarity, and 14% gaps) (88), while PSMA has a more compact
dimer interface and an enzymatically active site. The helical domain of TfR is the primary
site for Tf and HFE interaction and dimer contacts. In contrast, the residues in the helical
domain of PSMA involved in Tf and HFE binding are nonconservatively substituted (88),
resulting in no Tf or HEF binding ability. The helical domain in PSMA only involves in
forming the dimer interface and the substrate‐binding cavity. The apical domain of TfR is
equivalent to the protease‐associated domain, a homology domain that can be found in
the non‐catalytic part of several families of the subtilases and zinc‐containing
metalloproteases, inserted within a loop of the peptidase domain of family M8/M33
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zinc peptidases (89,90). The function of the apical domain may relate to mediate
substrate determination of peptidases or form protein–protein interactions (89). In
PSMA, the apical domain contains the binding site of the J591 antibody (91), but the
function in TfR is unclear. The currently available models of Tf/TfR suggest that this
domain does not participate in Tf binding. Some studies have shown that the apical
domain of TfR may participate in some viruses (e.g., arenaviruses (92) and canine and
feline parvoviruses (93)) and ferritin (94) binding, evolved to not interfere with Tf
binding. The protease‐like domain in TfR is closely related to that of carboxy‐ or
aminopeptidase family and it is highly conserved in TfR/PSMA family (53% identical to
TfR2 (79)) and 29% identical to PSMA (88)). Unlike TfR, the protease domain of PSMA
contains a binuclear zinc site, catalytic residues, and a proposed substrate‐binding
arginine patch (88). The active site and the substrate‐binding cavity in PSMA are formed
with a contribution of all three domains. The two Zn atoms, a catalytic water (or OH‐),
and their coordinating residues (histidine and glutamate/aspartate) in the active site are
highly conserved between PSMA orthologs and related Zn‐dependent exopeptidases
(for example, Streptomyces griseus aminopeptidase (Sgap), Aeromonas proteolytica
aminopeptidase (AAP), peptidases V and T (PepV and PepT), and carboxypeptidase G2
(CPG2)) (88). In TfR, four out of the five presumed Zn‐binding ligands (His553, His377,
Glu425, and Asp387, with the sole exception of Asp453 in PSMA) in the protease‐like
domain are missing, and TfR lacks the protease activity. The substrate‐binding cavity is
undisputedly one of the most important portions in PSMA which is shaped by Phe209,
Arg210, Asn257, Glu424, Glu425, Gly427, Leu428, Gly518, Tyr552, Lys699, Tyr700, and
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an arginine‐rich patch (Arg‐210, ‐463, ‐534, and ‐536) (88,95). A beta‐hairpin, residues
692‐704 in PSMA termed the glutarate sensor (red arrow in Figure 1‐6B), which is
reported to be important for its substrate recognition and/or binding (95), contains
insertions in PSMA (relative to TfR) and exhibits unique seconder structure element in
PSMA which is not present in TfR. This beta‐hairpin connects the helical domain to the
rest of PSMA, but it is much shorter in TfR and unable to reach into the substrate‐
binding cavity in PSMA.
Since the protein function is directly related to its 3D structure, any change to a
protein at any structural level, including slight changes in the folding and shape of a
protein, may render it nonfunctional. PSMA, function as an enzyme, the specific shape
and configuration allows the formation of active site and substrate‐binding cavity. In TfR,
the missing of the Zn‐binding ligands and the different shape of the substrate‐binding
cavity lead to the loss of the enzyme function. Instead, the residues in TfR involved in Tf
and HFE binding, as well as TfR/TfR dimerization, are nonconservatively substituted in
PSMA. We argue that TfR function had to co‐evolve with that of Tf (MTf
(melanotransferrin)/Tf split), likely before the true vertebrates arose (Figure 1‐7) (50,79),
and the sequences/structures divergent from PSMA and were kept in TfR are
responsible for its new function (including the pH‐dependent preference for apo and
holo forms of Tf).
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Figure 1‐6 The structural alignment of sTfR1 (PDB: 1CX8) (left) and PSMA (PDB: 2OOT)
(right) highlighting the insertions (A) and structure comparison (B). (A) The insertions in
TfR (relative to PSMA) are colored in pink, and the insertions in PSMA (relative to TfR)
are colored in red. (B) The helices and β‐strands that common to both TfR and PSMA are
colored in green and orange, respectively. The helices and β‐strand that unique to PSMA
are colored in slate and magentas, respectively. The two zine atoms in PSMA are
highlighted in cyan dots and the zinc binding sites are shown in blue in panel A. The
residues formed the substrate‐binding cavity are highlighted in yellow. The red arrow in
panel B is pointed to the glutarate sensor in PSMA, and the analogous region in sTfR1 is
also pointed.
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Figure 1‐7 Relative evolutionary relationships among Tf family members (A) and
TfR/PSMA family (B). Numbers on the branch represent the percentage of 1000 for Tf
family and 2500 replicates for TfR/PSMA family in which each cluster was formed. Tree
B was produced using one representative from each major group of sequences. Figure A
and B are reproduced from reference (50) and (79), respectively. ICA: inhibitor of
carbonic anhydrase. LTF: lactoferrin. OTF: ovotransferrin. SAX: saxiphilin. BI: ciona Tf2.
MONO: ciona Tf1. OMP1: otolith matrix protein 1. PAC3: pacifastin 3. TTF: triplicated
transferrins.
Mass Spectrometry as a Tool to Study Protein Structure and Function
Contributions of Mass Spectrometry to Structural Proteomics
The term ‘proteome’ was first used in 1995, to describe the entire complement
of protein (96). The derived word ‘proteomics’, which is used quite commonly, deals
with the large‐scale study of protein properties, especially their structures, functions,
and control of biological processes (97,98). This field is a collection of various techniques,
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including protein separation, identification, quantification, and analysis. In the post‐
genomic era, mass spectrometry (MS) has increasingly become the method of choice for
protein bioinformatics analysis because of its high throughput in analyzing the protein
primary sequence, post‐translational modifications, and protein‐protein interactions.
MS‐based methods are also being developed to determine both higher order structure
and the dynamics of proteins as well as protein complexes, which successfully
complement other biophysical techniques, including X‐ray crystallography and nuclear
magnetic resonance (NMR) spectroscopy. In the recent revolution, the combination of
MS to other methods, such as hydrogen/deuterium exchange (HDX), cross‐linking, ion
mobility, limited proteolysis, and chemical modification has led to a new field of
structural proteomics. Each of these can provide unique characters for studying protein
structure.
Direct Electrospray Ionization Mass Spectrometry (ESI MS) Analysis of Protein
and Protein/Ligand Binding
ESI MS works as an ionization technique allowing protein ions to be extracted
directly from the solution. It can be performed under gentle conditions and applied to a
wide range of analytes, especially for macromolecules as it is able to overcome the
propensity of these molecules to fragment when desorbed and/or ionized. A high
electric field of 3‐4 kV is applied to the tip of the capillary, which is situated in the ion
source of the mass spectrometer. In this strong electric field, the sample emerging from
the tip is dispersed into an aerosol of highly charged droplets by a co‐axially introduced
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nitrogen, flowing around the outside of the capillary. The charged droplets diminish in
size and increase in surface charge density by solvent evaporation, via a warm flow of
nitrogen passing across the front of the ion source. Finally, charged sample ions, free
from the solvent, are released from the droplets and pass through a sampling cone into
the analyzer of the mass spectrometer. ESI typically produces multiply charged ions with
a statistical distribution which effectively extending the mass range of the analytes from
kDa to MDa, and the extent of this multiple charging is determined by the physical
dimensions of the protein in solution (99). The number of charges for a denatured
protein (unfolded form) is greater than the native protein (folded from). By analyzing
the charge‐state distribution of protein ions in ESI MS, the integrity of the higher order
structure can be assessed.
Since the early 1990s, ESI MS has emerged as a versatile tool to study the nature
of the noncovalent protein/protein, protein/small molecule, and protein/DNA
complexes. It is a sufficiently soft ionization method, which allows noncovalent
biological complexes to be transferred intact from the solution into the gas phase under
appropriate instrumental conditions, and the observation of the complex in the gas
phase can indicate its interactions in solution. However, it should be noted that since
the hydrophobic interactions are weakened in solution compared with the hydrogen
bonds between water molecules (100), the protein/ligand complexes formed mainly
through the hydrophobic interactions are actually forced by the hydrophobic effect.
Thus, those complexes are prone to be dissociated when transfer from the solution into
the gas phase and, in this case, the observation in the gas phase does not correlate
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binding properties in solution. Conversely, electrostatic interactions and hydrogen
bonds are stronger in the gas phase than in the solution (100). So protein/ligand
complexes formed mainly through these forces can be retained in the gas phase.
Moreover, this technique measures the mass‐to‐charge ratio (m/z) with high
mass accuracy which can be used to directly determine the binding stoichiometry of
protein/ligand complexes based on their masses. One example is that ESI MS can be
used to probe the interactions of Tf with metals (for example, Fe3+ and In3+) and
synergistic anions by monitoring the compositions of the metal‐protein complexes and
their large‐scale conformational dynamics (58,101,102). The former approach can be
done by analyzing the mass of the protein ions, and the latter is performed by analyzing
the different charge state distributions.
Another advantage of the direct ESI MS assay is that it can combine with liquid
chromatography and additional MS‐based methods to further select and analyze the
complexes. Furthermore, a nanospray adaptation of ESI, nanoESI, can extend the
application of ESI MS to larger protein assemblies, such as oligosaccharides and
glycoproteins. It can significantly drop the amount of sample, increase the sensitivity
and efficiency, has better tolerance to salts and more efficient desolvation (103).
The Studies of Protein Conformation and Dynamics by Hydrogen/Deuterium
Exchange Mass Spectrometry (HDX MS)
In solution, protein molecules are not static, but rather are in the equilibrium of
interconverting states. Protein conformation and dynamics can be probed with various
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techniques, such as X‐ray crystallography and high‐resolution NMR. Although in many
cases these techniques can provide detailed structural information of the proteins or
protein complexes, their inherent limitations make the application for analyzing the
biopharmaceutical products impractical. For example, X‐ray crystallography requires the
protein to be crystallized prior to analysis, which makes it impossible to carry out the
direct examination of the protein conformation under certain relevant productions or
physiological conditions. Although high‐resolution NMR reveals the solution structure of
a molecule without crystallization, which is useful for the study of partially folded or
unfolded proteins that are difficult to crystallize, it is still restricted the physical size of
the protein systems (in general within 25 kDa).
During the past two decades, HDX in solution combined with ESI MS has become
a powerful tool to explore both protein conformation and dynamics under various
conditions (104‐108), as well as the protein/ligand interactions (109) and protein folding
(110) by obtaining deuterium content across the polypeptide backbone at either
peptide or protein level. The high sensitivity and mass accuracy make MS an ideal
technique for monitoring a 1 Da mass shift between hydrogen and deuterium. When
performing HDX MS, it measures the sum of all populations of molecules or peptide
segments in the sample solution. Each isotope cluster in the mass spectrum is reported
as the shape, the width, and the isotopic distribution. Any unusual information can
indicate

interesting

protein

dynamics,

conformational

heterogeneity,

and

interconverting states (111). This technique is reliable, sensitive and is capable of
visualizing various states of protein systems without crystallization.
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The rate of HDX is based on the solvent accessibility and hydrogen bonding of
the backbone segments. In a folded protein, protons that are buried in the protein
interior or are involved in the formation of hydrogen bonds on the secondary structure
(α‐helices and β‐sheets) are not able to exchange or exchange quite slowly unless they
become exposed to the solvent by a conformational change (112‐114). Besides these,
several other factors, such as pH, temperature, side‐chain, and isotope effects, can also
contribute to the HDX protection (115). Although the hydrogen atoms on the polar and
charged side chains are frequently exchanged very fast since they are exposed to the
solvent, the contribution of labile side chain hydrogen atoms to the overall exchange
rate can be easily eliminated during the digestion and LC separation by lowering the
solution pH to 2.5‐3 as well as the temperature to 0‐4°C, which result in a very slow
exchange rate for the backbone amide hydrogen atoms (average exchange rate 10‐4 s‐1)
(109,116,117), except for the N‐terminal residue (exchange rates >10 s‐1) (118). Since
HDX measurement focuses on the exchange of the backbone amide hydrogen atoms, it
allows the measurement to achieve a single residue level resolution (with the exception
of proline).
The kinetics measured in HDX depends on both protein dynamics and intrinsic
amide hydrogen exchange rates. The mathematical formalism used to describe protein
hydrogen exchange as a two‐step process was introduced by Hvidt and Nielsen several
decades ago (119):

(1)
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where kop and kcl are the rate constants for the opening (unfolding) and closing
(refolding) steps that expose/protect a particular amide hydrogen to/from exchange
with the solvent and kint is the rate constant for the intrinsic exchange reaction of the
exposed hydrogen. In general, the protected state represents the native state, whereas
the unprotected state describes a fully unfolded (random coil) state, a partially unfolded
(intermediated) state, or a structural fluctuation within a native conformation which
transiently exposes a protected amide hydrogen to solvent without large‐scale structure
loss. In most HDX studies, the observed rate constant for the exchange process, kHDX, is
given by

kHDX 

kopkint
kcl  kint

(2)

Two distinct exchange regimes are commonly identified in HDX measurements,
named EX1 (kint>>kcl) (Figure 1‐8B) and EX2 (kint << kcl) (Figure 1‐8A). HDX measurements
under native or near‐native conditions usually follow the EX2 kinetics (107,120), which
amide hydrogen atoms are exposed briefly in solution through fast local conformational
fluctuations. As a result, HDX under these conditions does not provide any kinetic rate
information at which conformational fluctuations occur but yields thermodynamic
information. Instead, nonnative HDX reactions favor the EX1 regime, where kcl is
decreased under denaturing conditions or kint is increased at high pH conditions. Proton
exchange occurs upon the first unfolding event, therefore this HDX behavior can reflect
the kinetic information of the unfolding event. Alternatively, a bimodal behavior may
also be observed in the intermediate EX1/EX2 exchange regime where the values of kint
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and kcl are comparable (kint ≈kcl) (Figure 1‐8C). The exposure time in the competent state
is long enough for one or more protons to exchange during each unfolding event (the
fast exchanging species) but too short for the entire set of all protons to exchange at
once. When HDX reactions follow EX1 or EX1/EX2 exchange regime, a distinction among
various conformations of protein coexist in the solution at equilibrium. As a result, these
types of spectra exhibit very convoluted exchange patterns as the form of bi‐ or multi‐
modal isotopic distributions of protein ions which can reveal two or more distinct
conformational states (121) or conformational heterogeneity in a sample (122,123). In
principle, isolating each individual sub‐distribution corresponding to a specific
conformer prior to fragmentation allows multiple conformers to be detected separately.

Figure 1‐8 Simulated HDX patterns for a two‐state system carried out under the
conditions corresponding to (A) EX2, (B) EX1 and (C) the intermediate EX1/EX2 exchange
regime.
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Inductively Coupled Plasma Mass Spectrometry (ICP MS) Based Methods for
Protein Quantitation
The accurate quantitation of the proteins is one of the essential prerequisites for
protein studies in multiple research topics. Several different techniques for the protein
quantitation have been suggested during the recent years, most of them are based on
the stable isotope labeling combined with mass spectrometry (ESI MS or matrix‐assisted
laser desorption/ionization mass spectrometry (MALDI MS)) (124). However, these
methods require a reference standard and specific labeling reagents, and the obtained
signal intensity in MS is ambiguous due to the diverse ionization efficiencies of different
proteins or peptides (97). In recent years, ICP MS has emerged as an attractive and
complementary approach to ESI MS and MALDI MS for protein quantitation. It is a
sensitive elemental detection technique in metallomics studies for measuring metal‐
and metalloid‐containing compounds and their interactions within biological systems
(125). Comparing with other methods, ICP MS has several unique characteristics. 1) It
uses a high temperature (6,000‐10,000 K) argon plasma as the ion source which can
readily break all chemical bonds in the sample and to generate positively isotopic
charged ions. As a result, 2) the response of an element in ICP MS is irrespective of its
compound structure or matrix effects. More importantly, 3) the limits of detection in
the absence of interferences from ubiquitous metals and plasma‐related ions can be
achieved at low fmol level (126,127). Besides, 4) ICP MS can combine with various
separation methods, such as gas chromatography, liquid chromatography, and capillary
electrophoresis. All these characteristics are propitious for ICP MS to be an ideal method
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for protein quantitation with high accuracy and low detection limit. Unfortunately, not
all elements can be detected by ICP MS. Many abundant elements, such as hydrogen,
carbon, and oxygen, most gaseous elements, and the elements without naturally
occurring isotopes, are hard to be ionized in ICP due to their high first ionization
potentials. In addition, there exist many polyatomic interferences in ICP MS that are
formed from precursors, such as the sample matrix, the reagents used in sample
preparation, argon plasma gas, and the entrained atmospheric gas. Such polyatomic
interferences are 40Ar16O+ on 56Fe, 14N16O1H+ on 31P, and 16O2+ on 32S. There are several
approaches can be used to overcome such polyatomic interferences: selecting an
interference‐free isotope for analysis, using the correction equations, and using a
technique termed collision/reaction cell which is used to promote reactive and non‐
reactive collisions that are responsible for polyatomic interference reduction in a gas
filled multipole located in front of the mass analyzer (128,129).
Imaging Mass Spectrometry of Biological Tissues
Biological imaging MS is one of the most important bioanalytical techniques
which are currently used for mapping the spatial distributions of multiple compounds
and molecules in investigated tissues in the fields of analytical and biomedical research,
providing a new tool for clarifying and understanding the molecular complexities of cells
and tissues.
MALDI MS is one of the popular imaging MS techniques for peptides, large
biomolecules, metabolites, and drugs (130‐134). This technique can be used to identify
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phosphorylation sites in proteins, but it cannot provide direct quantitative
determinations of phosphorus and metals in biological samples. Another commonly
used MS imaging technique is secondary ion mass spectrometry (SIMS), which can
produce images of the distribution of elements, isotopes, nanoparticles and small
molecules in tissues with a high spatial resolution (achieving submicrometer level) (135‐
137), but analyzing for large proteins still remains a challenge (138). It uses high energy
primary ions (such as Ar+, Ga+, Bi3+ with primary ion energies of several keV) to strike the
sample surface, which sputter both neutral and charged secondary species from the
sample. However, the excessively hard ionization can also lead to severe in‐source
fragmentation (139). Up to six orders of magnitude of the inherent matrix effects can
significantly affect the quantification of the images (140,141). Besides MALDI and SIMS,
a new category of methods, ambient ionization, such as desorption electrospray
ionization (16,142) and matrix‐assisted laser desorption electrospray ionization
(MALDESI) (143), has been also employed for imaging with little or no need for sample
preparation (144). However, precisely because lacking sample preparation and
enrichment, the intrinsic poor sensitivity for ionization of peptides and proteins
comparing to MALDI can be particularly problematic in experiments.
Due to the serious quantitative problems of the above methods, an alternative
approach, laser ablation inductively coupled plasma mass spectrometry (LA‐ICP MS), has
been established as a powerful imaging MS technique that can be used directly to
quantitatively analyze the distributions of elements and isotopes at the trace and the
ultratrace concentration level in microtome thin tissue sections (optimum at 20‐30 μm
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thickness) of biological matrices (140,145,146). LA‐ICP MS was initially established for
analyzing the elemental and isotope compositions in geological and archeological
samples from the 1980s (147,148) and was later applied to describe the trace elemental
distributions in biological tissues (149,150). It is a fast and high sample throughput
technique with minimal sample preparation and high sensitivity, accuracy, and precision
(145). The principal schematic of elemental imaging LA‐ICP MS is illustrated in Figure 1‐9.
A laser beam is focused onto the surface of the thin tissue slice and scanned line by line.
The sample is ablated, gasified, and then carried by the carrier gas (He and/or Ar) into
ICP MS for ionization and detection.

Figure 1‐9 Principles of imaging MS technique by LA‐ICP MS. A thin biological tissue
section is ablated by a focused laser beam in the laser ablation chamber. Then the
ablated material is analyzed by ICP MS, and metal ion images are constructed.
Reproduced from reference (145).
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Aims and Outlines of the Dissertation
TfR‐mediated endocytosis has been explored as an efficient pathway for
therapeutic molecules and protein delivery. It is clear that successful implementation of
such strategy will critically depend on:


Aim 1: Detailed understanding of the binding mechanism of multiple forms of Tf/TfR
at both neutral and acidic pH and the role of TfR participating in iron release from Tf



Aim 2: Develop sensitive and reliable assays that would monitor the biodistribution
of exogenous Tf and Tf‐based drugs in tissues and reliable measurements of their
levels in blood and other biological fluids
TfR is unusual in that its binding preferences are tuned by pH, with the holoTf

being strongly favored at neutral pH and the apoTf favored at endosomal pH. Although
the crystal structures of apoTf (74), Fe2Tf (151), TfR (63), and TfR coupled with the HFE
protein (76) and FeNTf (65) have been determined for some time, they mainly focus on
the TfR behaviors at neutral pH and the structures of free TfR and it coupled with Fe2Tf
and apoTf at acidic pH remain elusive and evade many crystallographic efforts (Figure
1‐10A). Moreover, a single, static picture is far from enough to understand the whole
picture of TfR‐mediated endocytosis. To address these issues and achieve the Aim 1, MS
coupled with HDX was used as a tool in this work to investigate the structural changes
and conformational dynamics of TfR binding with different forms of Tf under different
conditions that mimic various stages encountered during endocytosis and a proposed
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mechanism of Tf/TfR interaction throughout the endocytotic cycle was described in
CHAPTER 2.
To achieve the Aim 2, metal labeling combined with ICP MS detection (Figure
1‐10B) was developed and validated for detection/quantitation of exogenous Tf in
biological samples (CHAPTER 3). We take advantage of the two metal binding sites in Tf,
by which a constant metal to protein ratio (2:1) can be achieved, and the ability of Tf to
bind a wide range of other metals (gallium and indium). In addition to the iron binding
site, we also explore the utility of the His‐tag, a histidine‐rich segment of the
recombinant Tf as a potential site for nickel tagging. This study demonstrated the
feasibility of using indium as a potential tracer of exogenous Tf and using ICP MS
method to quantitate In2Tf in biological samples and image it in organ cross‐sections.

Figure 1‐10 Schematic diagram of (A) Tf/TfR binding mechanism and (B) the process of
metal labeling and ICP MS detection. The panel (A) is from Reference (66).
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TRANSFERRIN RECEPTOR CONFORMATIONAL DYNAMICS AND INTERACTIONS WITH
TRANSFERRIN STUDIED BY HYDROGEN/DEUTERIUM EXCHANGE MASS SPECTROMETRY
Project Goals
TfR, as a carrier protein for Tf, has different Tf binding affinities at different pH
levels, with high holoTf binding affinity at neutral pH and high apoTf binding affinity at
endosomal pH. Thus, the pH sensitivity of the interactions of holo‐ and apoTf with TfR
are critical to the receptor‐mediated endocytosis. In this chapter, we use HDX MS as a
tool to investigate the conformational dynamics changes of TfR in different Tf/TfR
models to explore the detailed molecular mechanism of Tf/TfR interactions throughout
the endocytic cycle and the role of TfR participating in iron release in the endosome. In
the present work, following major questions have been addressed:


How does the conformation of TfR change when it binds to holoTf at pH 7.5?
Comparison of HDX data of TfR in the absence and the presence of holoTf at pH
7.5 is used to evaluate the conformational change within TfR as a result of Tf binding.
It is expected that significant differences will be observed in/near the
crystallographically identified Tf/TfR interface regions (the helical domain and the N‐
terminus of TfR), while extra protection afforded by Tf to TfR could provide a means
to localize regions within TfR, which are affected indirectly by the binding, are also
essential to the binding of Tf.



Are there any specific conformational transitions occur within TfR at different pH
levels which modulate its ability to bind holo‐ and apo‐forms of Tf?
36

We compare the HDX data of TfR at pH 7.5 and 5.5 (“neutral” and “acidic” state
of TfR, respectively). Any changes of the backbone protection pattern of TfR upon
acidification could help to characterize the pH‐induced conformational change of TfR
that primarily affects TfR binding selectivity by pH.


What’s the mechanism of environmental regulation of the receptor binding
selectivity: How TfR help iron release from Tf and do not allow apoTf release from
TfR at pH 5.5? Why apo Tf dissociate from TfR at pH 7.5?
This is achieved by using HDX MS to characterize the Tf/TfR binding interface on
the holoTf/TfR and apoTf/TfR complexes at both pH 7.5 and 5.5. It is expected that
the different forms of Tf have site‐specific interaction regions on TfR. The analysis at
pH 5.5 correspond to the binding interface between the “acidic” state of TfR and the
closed and open conformation of Tf, respectively, that account for its role in
participating iron release and attribute to apoTf binding, while the analysis at pH 7.5
correspond to the binding interface between the “neutral” state of TfR and the
closed and open conformation of Tf, respectively, that response to its high holoTf
binding affinity and the dissociation of apoTf. The combination of the information of
the conformations of “neutral” and “acidic” state of TfR and the site‐specific Tf/TfR
binding interfaces at neutral and acidic pH could lead to a better understanding of
the molecular mechanism of modulation of TfR binding selectivity by pH.
In addition to process the HDX data, we extend our exploration for the

structure/function of TfR to the molecular evolution of the TfR/PSMA family. The distant
relatives of TfR are proteases (such as PSMA). Despite having strikingly similar 3D
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structures (Figure 1‐6), TfR and PSMA interact with their partner proteins in a very
different fashion. We argue that the TfR segments showing significant divergence from
PSMA are likely to harbor structural elements that are responsible for its new receptor
function, including the pH‐dependent preference for different forms of Tf, or the loss of
the enzyme function. Once the new receptor function was acquired, it was conserved
and should prevent further mutations within the relevant region. To achieve this, we
apply the sequence‐structure homology approach between PSMA and TfR to identify
important segments within TfR and compare with the HDX data help to answer the
above questions.
Materials and Methods
Protein Materials
To mimic the receptor‐mediated endocytosis, several protein samples were used
in this work: free TfR (N251D) (the sequence can be found in Figure 2‐2), Fe2Tf/TfR and
apoTf/TfR complexes at pH 7.5, as well as free TfR (N251D), Fe2Tf*/TfR
(K206E/R632ATf/TfR) and apoTf/TfR complexes at pH 5.5. The apo‐form of Tf was
produced by washing the nonglycosylated Fe2Tf with 1 mM EDTA in 3% (v/v) CH3CO2H,
followed by buffer exchange to 150 mM ammonium acetate, pH 7.5. A mutant Tf
molecule, K206E/R632ATf (Fe2Tf*), in which iron is locked into each of the two
homologous lobes of Tf by reducing the iron release rates by 2‐4 orders of magnitude
compared to the wild‐type Tf (45,61), was used to bind with TfR at pH 5.5. The Fe2Tf/TfR,
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Fe2Tf*/TfR and apoTf/TfR complexes were prepared by incubating molar excess Fe2Tf,
Fe2Tf* and apoTf with TfR at pH 7.5 and 5.5, respectively, for 30 minutes.
All protein samples listed above were generously provided by Professor Anne B.
Mason (University of Vermont, College of Medicine).
Protein Purification
TfR was first mixed and incubated with molar excess Fe2Tf, Fe2Tf* and apoTf in
150 mM ammonium acetate at pH 7.5 and 5.5, respectively. All free TfR and the Tf/TfR
complexes were then purified by size‐exclusion chromatography (SEC) with a mobile
phase of 150 mM ammonium acetate at the corresponding pH values. SEC purification
was carried out using Agilent 1100 HPLC (Agilent Technologies, Santa Clara, CA)
equipped with GE Healthcare, Superose 12 column (30 cm ×10 mm) at a flow rate of
0.45 mL/min. The elution profiles were recorded by following the 280 nm absorbance.
The free TfR, as well as the Tf/TfR complexes fractions (highlighted in the boxes in Figure
2‐1A‐C), were collected and characterized by native nano‐ESI MS (Figure 2‐1E). The SEC
fraction of each sample was concentrated a day before the HDX experiment using
centrifugal membrane filters with a molecular weight cutoff of 30,000 (Amicon,
Millipore) to the final concentration about 12 μM (about 1.8 mg/mL for TfR and 3.7
mg/mL for the Tf/TfR complexes).
Since apoTf weakly binds to TfR at neutral pH, to estimate the dissociation of the
apoTf/TfR complex under the HDX experimental condition, the SEC purified fraction of
apoTf/TfR at pH 7.5 (the fraction highlighted in the black box in Figure 2‐1C) was

39

concentrated to about 3.7 mg/mL and diluted ten‐fold with 150 mM ammonium acetate,
pH 7.5, then reinjected into SEC column. The SEC profile of the reinjected apoTf/TfR
complex was shown in Figure 2‐1D.
Peptide‐Resolved HDX Measurements
H/D exchange was initiated by diluting the pre‐concentrated SEC purified protein
solutions ten‐fold into a D2O‐containing buffer at 25°C to final concentration about 1.2
μM. At designated times (30 seconds, 2 minutes and 10 minutes), an equal volume of
quench solution (6 M guanidine HCl, 250 mM tris(2‐carboxyethyl)phosphine HCl, 0.1%
formic acid) was added and rapidly mixed, yielding pH 2.5. The quenched protein
solution was immediately digested online using Waters Enzymate™ BEH Pepsin Column
(2.1 x 30 mm, 5 μm) using 0.1% formic acid in water at 100 μL/min. All peptides were
collected and desalted in an inline peptide trap for 4.5 minutes and then were resolved
by a Waters C18 column using a linear gradient of 5‐35% 0.1% formic acid in acetonitrile
over 7 minutes at 40 μL/min. Sample preparation for HDX experiments was performed
by a LEAP autosampler PAL (LEAP Technologies, Carrboro, NC). The LC/MS
measurements were performed on an ACQUITY UPLC system combined with a Synapt®
G2‐Si mass spectrometer (Waters Corporation, Milford, MA) acquiring in MSE mode.
To account for back‐exchange, experiments with fully deuterated control (the
endpoint) were performed. The endpoint sample was treated in a different way. A
certain amount of SEC‐purified TfR was first digested offline using custom prepared
pepsin beads (POROS) in 0.1% formic acid in water at 100 μL/min. After lyophilizing, the
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powder of TfR peptides was dissolved in a deuterated solvent (150 mM ammonium
acetate in 90%/10% D2O/H2O) and was equilibrated at 25°C for 30 minutes as fully
exchanged peptides. Following the quench step, the deuterated peptide solution was
manually injected into the ACQUITY UPLC, trapped, except the online immobilized
pepsin column, and analyzed by LC/MS by using the same protocol as described above
for the HDX experiments.
HDX Data Analysis and the Calculation of the Threshold of Significant Difference
The MSE data for undeuterated TfR were searched against the input sequence of
TfR (N251D) to generate the list of peptides using ProteinLynx Global SERVER (PLGS;
Waters). Peptides identified by PLGS were further filtered and analyzed using the
DynamX HDX Data Analysis Software (Waters) with minimum products per amino acid
0.3, max sequence length 20 amino acids. The deuterium exchanged peptide was
assigned based on the same retention time and theoretical m/z value by comparison to
the unexchanged peptide. The number of deuterium uptake (#D in Da) for each peptide
was calculated by the DynamX algorithm. The percentage of deuterium uptake level
(HDX%) for each peptide was calculated as follows: HDX% = (mt –m0)/(mEP –m0) ×100%,
with mt, the centroid mass at incubation time t; m0, the centroid mass of the
undeuterated control; and mEP, the centroid mass of the endpoint control.
To evaluate the differential HD exchange among different samples and avoid any
arbitrary comparisons (such as visual comparisons based on the heat maps, or using
absolute differences between HD exchange rates on the butterfly or difference plots), a
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two‐tailed student’s t‐test evaluation was used in this work to statistically identify if a
peptide exhibiting a significant difference in structural dynamics or not at each
exchange time point between different samples with the threshold of significance
setting to 95% confidence interval (P ≤0.05), as described by Houde, et al. (152).
Specifically, the simple average of all individual standard deviation (SD) values of the
difference in deuterium uptake level between two states (ΔDi,t) from triplicate analyses
was used to compute the standard error of the mean (SEM) for any mean ΔDi,t value.
Then multiplied the SEM value by the appropriate two‐tailed student’s t‐table value for
the 95% confidence interval (for n=3, degrees of freedom is 2, the t‐value is 4.303),
given an estimated 95% confidence interval value for any mean ΔDi,t value that was
calculated from triplicate analyses, which if exceeded would statistically be considered
as a significant difference in deuterium uptake level.
2.2.5 pH Dependence of Amide Hydrogen Exchange Rate
While the comparison of the deuterium exchange levels at different pH levels is
not straightforward, the pH of the HDX reaction is logarithmically correlated with the
exchange rate due to the different intrinsic exchange rates (kint) of each backbone
amides, where kint is strong pH‐dependent and sensitive to neighboring side chains (153‐
155). Lowering the pH from 7.5 to 5.5 decreases the overall intrinsic exchange rate kint
of amide protons of TfR by a factor of 55 (calculated according to previously defined
nearest neighbor effects (154,155) using the online Excel spreadsheet at
http://hx2.med.upenn.edu/download.html). In order to get a meaningful comparison at
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different pH levels, we deconvolved the pH effect by converting the on‐exchange times
at low pH condition into those at high pH condition to offset the difference in kint values,
as we compared local protection patterns obtained following 10 minutes of exchange at
pH 5.5 with those recorded following 30 seconds of exchange at pH 7.5.
Results and Discussion
2.3.1 Protein Purification and Initial Characterization of the Tf/TfR Complexes
The Tf/TfR complexes used in this work were prepared by incubating molar
excess Tf with TfR under each condition. In order to remove the excess Tf added during
protein preparation, improve the sensitivity and minimize the complexity of the MS and
HDX MS analysis, all free TfR and Tf/TfR complexes used in the HDX experiment were
firstly purified by SEC. The collected SEC fractions of each sample (highlighted in the
boxes in Figure 2‐1A‐C) were characterized by native ESI MS. As shown in Figure 2‐1E,
the purified TfR (the red trace) is homogeneous and Tf effectively binds TfR to form a
stable Tf/TfR complex with 2:1 stoichiometry (the black trace) without any
contamination of excess Tf or 1:1 protein‐receptor complex.
Our MS data confirm the presence of the apoTf2TfR complex at pH 7.5 (Figure
2‐1E), which is consistent with the previous study that apoTf can form relatively stable
complexes with TfR at neutral and mildly basic pH with the same stoichiometry as the
complexes formed by holoTf (44). However, the binding affinity of apoTf and TfR at
neutral pH is relatively low, with the kd value at 10‐7 M level, about 30 times lower than
the kd value of holoTf/TfR (66‐69). It should be noticed that the weak interaction could
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cause a fast dissociation of the analyte back into solution. Since in the HDX experiment,
the concentrated protein sample has to be initially diluted ten‐fold into an aqueous
buffer containing deuterium, the weak interaction makes it possible for a large fraction
of the apoTf/TfR complex to dissociate upon dilution. Therefore, it is necessary to check
the composition in the suspect apoTf/TfR solution at neutral pH. This was done by
collecting the SEC fraction of the apoTf/TfR complex (highlighted in the black box in
Figure 2‐1C) at pH 7.5, following the concentration and dilution processes that simulate
the deuterium exchange experimental conditions, and then rechromatographing on SEC.
As shown in Figure 2‐1D, the later elution peak (at 11.2 min) in the reinjected
chromatogram of the collected apoTf/TfR fraction, with the same elution time as Tf (the
blue dotted line), indicates the presence of the free apoTf, about 23% of the apoTf2TfR
complex (calculated by the SEC peak area of each species) dissociated at pH 7.5 during
the dilution process. The weak binding affinity and the quick dissociation of the
apoTf/TfR complex at pH 7.5 make it difficult to purify the apoTf2TfR complex without
interference from the free protein and/or the apoTf1TfR complex. However, even in this
relatively unfavorable condition, the major component in the solution, the apoTf2TfR
complex, can still keep at around 77% which is competent in the use of HDX
measurement.
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Figure 2‐1 SEC of TfR (A), apoTf (B) and the product of incubating TfR with molar excess
of apoTf (C) at neutral pH. The black, red, blue dotted lines in panel A‐D represent the
elution time of Tf/TfR complex, TfR and Tf, respectively. Dissociation of the apoTf/TfR
complex at neutral pH was investigated by reinjecting the highlighted apoTf/TfR SEC
fraction in panel C. The SEC of the reinjected apoTf/TfR fraction was shown in panel D,
where the later elution peak with the same elution time as Tf indicates the presence of
the free protein at pH 7.5. Colored boxes in panels A‐C indicate the SEC fractions
collected for each sample which were characterized by native ESI MS in panel E and
used in the following HDX experiments.
2.3.2 Peptide Mapping and Sequence Coverage of TfR under HDX MS Condition
Overall, 83 of the most abundant peptide fragments of TfR which are found in all
TfR and Tf/TfR complexes with 81% sequence coverage (Figure 2‐2), including most of
the residues playing important roles in Tf binding and some of the residues located at
the TfR/TfR dimer interface region, were used to characterize the local HDX protection
patterns of TfR in this work to identify changes in conformational dynamics within TfR
throughout endocytosis, with the aim of characterizing the binding mechanism of
multiple forms of Tf/TfR at both neutral and acidic pH levels. The majority of the missing
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sequence is due to the presence of the N‐linked glycosylations at Asn317 and Asn727
that may enhance enzyme resistance by reducing accessibility of pepsin to peptic
cleavage sites (156). Additionally, pepsin cleavage specificity also impacts the sequence
coverage of TfR, as the presence of His, Lys, Arg and Pro in the P1 position strongly
disfavors pepsin activity. Pepsin also discriminates against Pro in the P2, P2’ and P3’
positions, as well as His, Lys and Arg in P3 position (157). (The P1‐P1’ is the peptide bond
where the enzyme cleavage occurs. Amino acid residues are designated P1, P2, P3, etc.
and P1’, P2’, P3’, etc. in the N‐ and C‐terminal directions from the cleaved bond,
respectively.) The low cleavage probability of pepsin at these sites could produce larger
peptides that are rich in Pro, His, Lys or Arg. Since our limitation of the max sequence
length is 20 amino acids, the low cleavage probability of pepsin could cause sequence
missing for the Pro/His/Lys/Arg‐enriched sequences, such as the N‐terminus and amino
acids [684‐701].
Conformational Changes within TfR as a Result of Tf Binding at Neutral pH
2.3.3.1

Overall Conformational Signatures of TfR in Tf Binding
Evolution of the deuterium content of TfR reveals a wide range of protection

levels across the protein sequence (Figure 2‐2, Figure 2‐3A‐C and Figure 2‐4). Overall,
the protease‐like domain, consisting of seven β‐sheets in the center mixing with ten
flanking α‐helices, appeared to be more stable in HDX than the other two domains in
the free receptor. This should be not surprising since the folded conformation of the
protease‐like domain can restrict the solvent accessibility and the enhanced intrachain
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hydrogen bonds of the α‐helix and β‐sheet structural elements can also contribute to
the HDX protection (158,159).
Once holoTf bonded to the receptor, TfR became less flexible, as most of the
regions gained protection and kept protected during the time course (Figure 2‐2 and
Figure 2‐3), which reflects that binding with Tf can stabilize TfR. It should not surprise
that significant differences in HDX kinetics upon Tf binding were observed in/near the
crystallographically identified Tf/TfR interface regions (the N‐terminus and the helical
domain of TfR), the kinetics of deuterium uptake of some regions in the protease‐like
and the apical domains were also decelerated in its complex form, with the apical
domain which is far from the Tf binding interface had the least effect on Tf binding
comparing with the other two domains. HDX data provide a means to localize several
segments that are affected indirectly by the binding, indicating the apparent dynamic
conformational changes within TfR are essential to the binding of Tf.
Deuterium uptake profiles for most peptide segments revealed a single isotopic
distribution that increased in mass over the time course, suggesting that these regions
display the more common EX2 kinetic behavior. Interestingly, several peptide segments
located at the protease‐like and the apical domains exhibited bimodal isotopic
distributions in the free TfR and/or Tf/TfR complexes (highlighted in yellow in Figure 2‐2).
Two of these, [506‐522] and [523‐537] in the protease‐like domain, are closed to the Tf
binding site, while others are located at the edge of the interdomain cleft formed by the
three domains (Figure 2‐5A). The observation of the bimodal isotopic distributions in
HDX, which arises from the EX1 kinetic behavior or the heterogeneous conformational
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populations of the protein, can provide unprecedented insights into protein
conformational dynamics that cannot be characterized by static crystal structures or
other solution spectroscopy. Such understanding could support the functionally‐
relevant features of the protein. The detailed discussions about the bimodal peptides
are presented in CHAPTER 2.3.3.3, 2.3.3.4 and 2.3.3.5.

48

Figure 2‐2 Heat map of TfR in the absence (solid lines) and the presence (dashed lines)
of holoTf at pH 7.5. The level of deuterium incorporation (%HDX) for each time point
(from top to bottom: 30 seconds, 2 minutes, and 10 minutes) is rendered in colored
horizontal layers for each peptide. Secondary structure is indicated above the sequence.
The locations of the predicted Tf interaction sites and the TfR dimer interface based on
the crystal structure of FeNTf/TfR (PDB: 3S9N) are highlighted by a black box and a blue
oval, respectively. The protease‐like domain, apical domain and helical domain are
highlighted in purple, dark blue and green boxes in the sequence, respectively. The N‐
linked glycosylation sites (Asn317 and Asn727) are highlighted in red in the sequence.
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The peptides exhibited bimodal isotopic distributions in the free TfR and/or Tf/TfR
complexes are highlighted in yellow in the sequence.

Figure 2‐3 Mapping of HDX protection data on the crystal structure of the free TfR (PDB:
1CX8) (A‐C) and the holoTf/TfR complex (PDB: 3S9N) (D‐F) following 30 seconds (top
row), 2 minutes (middle row) and 10 minutes (bottom row) of deuterium exchange at
pH 7.5. Color coding reflects the protection of segments from highly protected (blue) to
highly flexible (red). The differences in the percentage of exchange (complex – free
receptor) are also shown in G‐I, following the same exchange time course. Residues not
observed are colored in white in structure A‐F and in black in structure G‐I. The N‐lobe
of Tf is colored in pink and the C1 subdomain of Tf is colored in green. One monomer of
TfR is shown in cartoon, while the other is shown as surface.
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TfR pH 7.5
holoTf/TfR pH 7.5
apoTf/TfR pH 7.5
TfR pH 5.5
holoTf/TfR pH 5.5
apoTf/TfR pH 5.5

Figure 2‐4 Deuterium uptake plots for all observable peptides of TfR in the free TfR
(black), holoTf/TfR (red) and apoTf/TfR complex (blue) at pH 7.5 (solid lines) and 5.5
(dashed lines). Error bars represent standard deviation values from three individual
experiments. The bold peptides display bimodal isotopic distributions in free TfR and/or
Tf/TfR complexes.
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Figure 2‐5 Structure alignment of (A) TfR (PDB: 1CX8) and (B) PSMA (PDB: 2OOT)
showing the positions of the peptides exhibit bimodal isotopic distributions in TfR. The
peptides are labeled and colored accordingly. The interdomain cleft in TfR and the
substrate‐binding cavity in PSMA are highlighted in yellow.
2.3.3.2

Conformational Changes at the TfR/TfR Dimer Interface
The ectodomain of TfR is a noncovalent homodimer that the helical domains

from each monomer make contacts with each of the three domains within the other
monomer, contributing substantially to the extensive dimer contact regions. Four
representative peptide segments located at the receptor dimer interface region, the
segment (ii) [475‐480], (iii) [670‐676], (iv) [677‐683] and (v) [731‐737] as shown in Figure
2‐6, were selected to investigate the structural dynamic changes. Upon holoTf binding,
all above peptides gained protection obviously (with the threshold of significance for
exchanging 30 sec, 2 min and 10 min is ±9%, ±10% and ±7%, respectively (see Method
2.2.4 for the calculation of the threshold of significance)). Unlike the other three peptide
segments (ii, iii and v), the peptide segment (iv) [677‐683] was highly protected even in
the free TfR (only ~20% backbone amide hydrogens exchanged to deuterium after 10
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minutes of the exchange reaction). This is likely because this segment is located deeply
in the dimer interface that limits the solvent accessibility (Figure 2‐6A) (the average
relative SASA (solvent accessible surface area, ranging from 0 to 100%) for this segment
in the free TfR is about 7.1%, computed using the online ASAView server
http://ccbb.jnu.ac.in/shandar/servers/asaview/ (160)). In contrast, the peptide segment
(i) [437‐350] located at the bottom of the protease‐like domain, not at the TfR/TfR
dimer interface region, exhibited a similar exchange behavior in free TfR and the Tf/TfR
complex (the difference in HDX% for the segment (i) at each time point is ‐1%, 4% and
6%, comparing with the threshold of significance ±9%, ±10% and ±7%, respectively). The
decrease in deuterium uptake level in the presence of Tf observing for the peptides
located at the TfR/TfR dimer interface region suggests a conformational change occurs
at the dimer interface upon Tf binding that brings the two TfR monomers close to each
other to restrict solvent access. This observation agrees with the changes observed in
HFE/TfR (76) and FeNTf/TfR (65).
Previous studies (65,76) also suggested the endosomal pH could trigger a chain
reaction that causes a pH‐induced movement at the TfR/TfR dimer interface, altering Tf
binding. To further evaluate the pH effect at the TfR/TfR dimer interface region, we
examined the deuterium exchange patterns for these representative peptides at
different pH levels (pH 7.5 exchanging for 30 seconds vs. pH 5.5 exchanging for 10
minutes to offset the intrinsic hydrogen exchange rate). As shown in Figure 2‐6D‐E, all of
these peptide segments exhibited very similar exchange behaviors in the free TfR, as
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well as in the holoTf/TfR complex, at different pH levels, suggesting the pH change has
minor to no effect on the local conformation at the TfR/TfR dimer interface region.
In summary, obvious protections from exchange were observed for several
peptide segments at the TfR/TfR dimer interface region upon Tf binding at neutral pH
which is due to the decrease of solvent accessibility, but no difference in protection
under different pH conditions. Given these data and the available crystal structures of
TfR, HFE/TfR and FeNTf/TfR, it is reasonable to suggest that binding with holoTf at pH 7.5
causes a local conformational change at the TfR/TfR dimer interface that brings the two
TfR monomers into proximate. Then the two monomers maintain their relative position
in the holoTf/TfR complex when lowering the pH to 5.5.
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Figure 2‐6 HDX data of the representative peptide segments at the TfR/TfR dimer
interface. (A) TfR crystal structure (PDB: 1CX8) highlighting the locations of the five
representative peptide segments. One TfR monomer is depicted in cartoon, while the
other one is shown as surface. (B) The mass spectra extracted for the five representative
peptide segments from TfR (red) and the holoTf/TfR complex (blue) at pH 7.5. The non‐
exchanged control and the fully deuterated spectra for each peptide are colored in black
and gray at the bottom, respectively. (C) The deuterium uptake bar graph calculated
from the panel (B) as the percentage of deuterium uptake level versus the exchange
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time for the five representative peptide segments from TfR (red) and holoTf/TfR
complex (blue) at pH 7.5. The error bars represent the SD over three independent runs.
(D‐E) Comparison of the deuterium uptake levels of the five representative peptide
segments from TfR (D) and holoTf/TfR complex (E) at pH 7.5 exchanging for 30 seconds
(black) and at pH 5.5 exchanging for 10 minutes (gray).
2.3.3.3

Local Structural Dynamics of TfR in the Protease‐Like Domain
The conformational flexibility of TfR in the absence and the presence of Tf was

examined, revealing the protease‐like domain of TfR was relatively stable, especially for
the regions buried inside in the protease‐like domain (Figure 2‐2 and Figure 2‐3). While,
the N‐terminal α‐helix, peptide segment [128‐140], exchanged rapidly even in the free
TfR, as its deuterium uptake level reached to 61% by exchanging for 30 seconds (the
deuterium uptake levels for the helices in the helical domain ranged from 19% to 49%
by exchanging for 30 seconds) (Figure 2‐3A and Figure 2‐4), and was protected in the
holoTf/TfR complex (the difference in HDX% is 12% with the threshold of significance is
±9%), suggesting this N‐terminal helix might be not rigid and nearly unstructured in the
free TfR, but be stabilized by Tf binding. The N‐terminus of this helix contains several
contacts (Leu122, Tyr123, Trp124, and Asp125) with the N2 subdomain of Tf (65).
Although the HDX data for these N‐terminal contacts were missing, we predicted they
were protected upon Tf binding, and the protection extended into the rest of the helix.
Another notable change of the deuterium uptake pattern in the protease‐like
domain of TfR was observed for two adjacent peptide segments, [523‐537] and [506‐
522] (Figure 2‐5A). The mass spectra recorded for both peptide segments displayed
multimodal exchange patterns in the free protein and Tf‐bound forms (Figure 2‐7),
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suggesting the presence of the local conformational heterogeneity within this region in
solution.
The segment [523‐537] is located between the helix α7 and α8 of the protease‐
like domain and does not show any secondary structure (63), and the segment [506‐522]
is derived from the helix α7 and connected to the segment [523‐537] (Figure 2‐5A). As
shown in Figure 2‐7A, the peptide segment [523‐537] populated two conformations in
the free receptor, one was nearly fully exchanged and the other was almost fully
protected. When holoTf bound to the receptor at pH 7.5, the higher m/z population
became and remained constant as the major component in the holoTf/TfR complex,
indicating a local unfolding event occurred within this region upon Tf binding as early as
30 seconds of the exchange to give a state that underwent fast H/D exchange. This
highly flexible conformation, which often leads to high binding specificity (161),
contributes to stabilizing the holoTf/TfR complex at neutral pH by lowering the energy
barrier in Tf binding due to the increasing entropy at the binding transition states with
flexibility (161). Interestingly, detailed inspection of the mass spectra for this segment in
holoTf/TfR and apoTf/TfR at pH 5.5 revealed a unique trimodal isotopic distribution at 2
minutes of the exchange but not at the shorter or longer exchange time points nor in
the free TfR, suggesting the presence of a transient partially unfolded intermediate in
the Tf/TfR complex formations in solution (the population described in the green curve
in Figure 2‐7A). Moreover, this intermediate was the major component in the holoTf/TfR,
but as equal to the other two components in the apoTf/TfR. The difference observed
here suggests this region may participate in stimulating iron release in the endosome.
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Two overlapping peptide segments in this region, [529‐537] and [530‐537], also
exhibited bimodal isotopic distributions in the free TfR and Tf/TfR complexes at pH 7.5,
as those observed in the peptide segment [523‐537] (Figure 2‐7B‐C). While within each
peptide segment, it exhibited similar HDX profiles between the holo‐ and apoTf/TfR
complexes at pH 5.5 and there is no sign of the partially unfolded intermediate as
observed in the segment [523‐537]. Since these three overlapping peptide segments
align at the C‐terminus and the partially unfolded intermediate was only observed in the
segment [527‐537], but not [529‐537] nor [530‐537], it is reasonable to propose that the
transient partially unfolding event at pH 5.5 was occurred within the region [523‐528]
that participating in stimulating iron release from Tf in the endosome. Investigating the
structure of FeNTf/TfR, the region [523‐528] does not make any direct contact with iron‐
loaded Tf but it is located in proximity to the bridge between the N‐ and C‐lobe of Tf
(residues 332–340) (65,162) (Figure 2‐8). At acidic pH, we suggest the conformational
change of this region influences the bridge in Tf by forming a new cation‐π interaction
through Trp528 in TfR with Lys340 in Tf, resulting in movement of the bridge to
accommodate Tf clefts opening. Indeed, the positions of the bridge in the structures of
apoTf and FeNTf/TfR are different, implying that the loss of iron from the N‐lobe
accompanies the movement of the bridge (65).
The segment [506‐522] also exhibited clear two isotopic distributions in the free
receptor (Figure 2‐7D) which were probably due to its conformational heterogeneity,
the presence of the different ensembles (helix‐loop), and the contribution of the flexible
loop. It is interesting to note that in the free TfR at pH 7.5, the low m/z population
63

shifted to higher m/z range at 2 minutes of exchange but shifted back at 10 minutes of
exchange, suggesting a transient unfolding/folding transition occurs within this region,
which is probably caused by the helix‐coil transitions that typically for helical edges
(163). This change was not observed in the free TfR at pH 5.5 which could be due to the
low intrinsic exchange rate at the lower pH level. Once Tf was bound to TfR, the low m/z
population shifted to higher m/z as early as 30 seconds of exchange and it became and
remained as the major component, suggesting binding to Tf could induce the local
unfolding event. Moreover, the HDX profiles look similar in the different forms of the
Tf/TfR complex at pH 5.5, indicating this region does not involve in iron release process.
Although based on our current understanding, there is no evidence indicating that any
residue within the segment [506‐522] is involved in Tf binding, the allosteric effect by
protein binding could also cause the non‐interfacial sites to undergo a different HD
exchange behavior (164). The conformational change of this segment upon Tf binding
could be induced by the allosteric transition through its adjacent loop [523‐537].
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Figure 2‐7 The m/z spectra of TfR peptic segment (A) [523‐537], (B) [529‐537], (C) [530‐
537] and (D) [506‐522] in the absence and the presence of the binding partner at
different pH levels. The spectra of the peptide segment [523‐537] in Tf/TfR complexes at
pH 5.5 after 2 minutes of the exchange were fitted to a trimodal distribution (population
1: blue curves; population 2: green curves; population 3: black curves). The non‐
exchanged control (black trace, labeled as H2O) and the fully deuterated spectra (gray
trace, labeled as D2O) are shown at the bottom.
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Figure 2‐8 Structure of Fe2Tf/TfR (PDB: 1SUV) showing the locations of the region [523‐
528] in TfR (PDB: 3S9N) (green) and the bridge between the N‐ and C lobe of Tf ([332‐
340] (magentas). The suggested interaction Lys340 ‐ Trp528 at acidic pH is illustrated.
2.3.3.4

Binding to Tf Stabilize the TfR Apical Domain
TfR consists of three domains: a protease‐like domain, an apical domain, and a

helical domain. There is also an interdomain cleft formed by the portions of the three
domains (Figure 2‐9A). Careful examination of the HDX profiles revealed clear bimodal
isotopic distributions for several noncontiguous peptide segments located at the edge of
the cleft (Figure 2‐9A), [188‐201], [212‐225], [281‐295] and [557‐572], in the free TfR as
early as exposing to the deuterated buffer for 30 seconds (Figure 2‐10A‐C and Figure
2‐11). Interestingly, in the Tf/TfR complexes, these peptides exhibited a single isotopic
distribution that shifted to the relative high m/z range as early as 30 seconds of the
exchange, except for that in the apoTf/TfR at pH 7.5. In the apoTf/TfR complex at pH
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7.5, these peptides exhibited bimodal isotopic distributions, which could be due to the
weak apoTf binding affinity and the rapid dissociation under the relatively unfavorable
condition (the SEC data indicated about 23% apoTf/TfR was dissociated at pH 7.5 under
the HDX experimental condition (Figure 2‐1C‐D)). In contrast to the above peptide
segments located at the cleft region, a loop segment [346‐356], for example, located at
the opposite position of the interdomain cleft in the apical domain (Figure 2‐9A)
exhibited single isotope distribution in all free receptor and the complex forms, and the
presence or the absence of Tf did not influence its deuterium uptake level obviously
(Figure 2‐10D). Notably, unlike other reported bimodal patterns, which are induced by
ligand binding (165,166), the above peptide segments exhibited bimodal isotopic
distributions in the absence of the binding partner but single isotopic distribution in the
complexes. Given their close spatial proximity to one another and location at the
interdomain cleft, we suggest the observed bimodal isotopic distributions could result
from the heterogeneous conformations of TfR in solution and Tf binding could induce
the local conformational fluctuations at the interdomain cleft region that transit the
slow exchanging conformation into the fast exchanging conformation.
In TfR, the apical domain forms a lid structure that covers the interdomain cleft.
It flexibly connects with the protease‐like domain by two β strands which act as a hinge,
allowing small rotation of one domain relative to the other (63). Based on the different
conformations observed for the peptide segments located at the interdomain cleft
region in HDX and the flexibility of the apical domain, we propose that the interdomain
cleft in TfR appears to have different 3D shapes in solution based on the different
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positions of the apical domain: the Position I and II as shown in Figure 2‐9B which
represents a relatively closed and an open state, respectively. For the peptide segments
display bimodal isotopic distributions, the species representing the fraction of the slow
exchanging, solvent‐restricted population correspond to the Position I (closed), whereas
the species representing the fraction of fast exchanging, solvent‐accessible population
correspond to the Position II (open). In the free TfR, the two different conformational
structures coexist in equilibrium in solution. Binding with Tf causes a shift of the species
to fast exchange, suggesting the conformation of the cleft is stabilized into a relatively
open position (the Position II). At acidic pH, the single high m/z species observed in HDX
in the Tf/TfR complexes indicate the interdomain cleft maintains this conformation
through the endocytic cycle until the complex returns back to the cell surface. In the
apoTf/TfR complex at pH 7.5, the weak binding affinity of apoTf makes the apical
domain flexible again and the interdomain cleft more favorable at the closed position,
as the larger percent of the low m/z population in apoTf/TfR complex comparing with
those in TfR at pH 7.5.
Previous studies (65,72,75) suggested the Tf binding sites on TfR are on the
helical domain and the N‐terminus of the protease‐like domain which are distant from
the interdomain cleft ((Figure 2‐9A). Clearly, these changes in the conformation of the
interdomain cleft upon Tf binding are not induced by direct protein‐protein interaction,
allosteric effects must attribute to it. Investigating the structures of free TfR and TfR
bound to Tf, a disordered loop in the apical domain (residues 306‐330) (Figure 2‐12),
involved in TfR dimerization and Tf binding, rotates towards the Tf binding site when Tf
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is present (65). We propose that Tf binding triggers a perturbation of the hydrogen‐
bonding network around the interdomain cleft through this disordered loop (His318 in
TfR interacts with His349 in Tf) and that causes the conformational change of the apical
domain. In addition, since the allosteric regulation generally alters the entropy and
enthalpy and, therefore, regulates protein function (167), the conformational entropy
changes due to the loss of the flexibility of the apical domain upon Tf binding could
further enhance the strength of the interactions of TfR with Tf and stabilize the complex.

Figure 2‐9 TfR interdomain cleft. (A) Locations of several peptide segments located at
the interdomain cleft that exhibiting bimodal isotopic distribution. A control peptide
segment [346‐356] showing single isotopic distribution is highlighted in blue. TfR is
colored in white, the C1‐Tf subdomain is colored in cyan, and the N‐lobe of Tf is colored
in orange. The interdomain cleft is highlighted in yellow and the predicted Tf binding
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region in TfR is highlighted in the black box. (B) Schematic diagram of the two relative
positions of the apical domain of the free TfR that may coexist in the solution. H: the
helical domain; A: the apical domain; P: the protease‐like domain.

Figure 2‐10 The m/z spectra of the peptic segment (A) [188‐201], (B) [281‐295], (C) [557‐
572], and (D) [346‐356] in the absence and the presence of the binding partner at
different pH values. The non‐exchanged control (black trace, labeled as H2O) and the
fully deuterated spectra (gray trace, labeled as D2O) are shown at the bottom.
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Figure 2‐11 The m/z spectra of several overlapping peptic segments located at the edge
of the interdomain cleft in the absence and the presence of the binding partner at
different pH values. The non‐exchanged control (black trace, labeled as H2O) and the
fully deuterated spectra (gray trace, labeled as D2O) are shown at the bottom.
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Figure 2‐12 Structure of Tf/TfR showing the position of the disordered loop [306‐330] in
TfR (magentas) rotates towards the Tf binding site in the presence of Tf (blue). TfR is
colored in white. The interdomain cleft is highlighted in yellow. The Tf molecule has
been removed with the exception of the segment [347–364] (cyan).
2.3.3.5

Structural Comparison of TfR and PSMA
Despite TfR has a strikingly similar 3D structure to that of PSMA (Figure 2‐5) (the

structure of the protease‐like domain, the apical domain, and the helical domain is 29%,
25%, and 23% identical to PSMA, respectively) (88), its function as a receptor rather
than an enzyme. Since the function of a protein is directly dependent on its 3D
structure, we propose the structural divergence of TfR/PSMA in molecular evolution is
necessary for the evolution of new functions or the loss of former functions for TfR.
After aligning the sequences of TfR and PSMA (Figure 2‐13), we found all TfR
peptide segments exhibiting bimodal isotopic distributions in HDX have a small or large
number of deletions compared with the analogous regions in PSMA. These regions are
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conserved within each subfamily within vertebrates but variable between the TfR and
PSMA subfamilies. In PSMA, these regions are involved in forming the substrate‐binding
cavity and the insertions contribute to a large increase in buried surface area between
the apical and protease domains (about 2‐fold larger than that in TfR (88)) and narrow
its substrate‐binding cavity (Figure 2‐5). In TfR, the fact of the deletions at the edge of
the cavity and the reduced area of the substrate‐binding cavity could allow
interferences with substrates access that leads to the loss of the enzyme function in
molecular evolution. Comparing with PSMA, TfR has less interdomain contacts, making
the apical domain more flexible in solution. This was demonstrated by the observation
of the presence of the two different conformations in HDX for the segments located at
the TfR interdomain cleft edge (CHAPTER 2.3.3.4). It is interesting to note that structural
alignment analysis of the TfR region 506‐537 shows the analogous region in PSMA has a
unique short α‐helix (PSMA residues 492‐502) which is highly conserved within PSMA
family but not present in TfR (Figure 2‐5 and Figure 2‐14). The loss of the short helix in
TfR in the molecular evolution could increase the flexibility of this region (with large
crystallographic b‐factors in TfR) which could assume multiple conformations and
induce the structural fluctuation due to the large inherent conformational entropy. We
suggested at acidic pH the Trp528 in TfR could form a cation‐π interaction with Lys340 in
Tf that induce the movement of the bridge connecting the N‐ and C‐lobe of Tf to
accommodate Tf clefts open. Although the residue Trp528 is completely conserved in
TfR and PSMA, it is involved in helix packing in PSMA (Figure 2‐14), making it not easy to
approach the binding partner.
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Figure 2‐13 Sequence homology between TfR and PSMA subfamilies. The graph is
generated using the online software Jalview (http://www.jalview.org/). The calculated
quantitative alignment conservation annotation is measured as the number of
conserved physico‐chemical properties conserved for each column of the alignment
(168). The residues which are completely conserved within each subfamily are
highlighted in blue on the sequence. The peptide segments exhibited bimodal isotopic
distributions in TfR are highlighted with red bars on the top of the sequence. The two
peptide segments, [628‐636] and [702‐712], exhibited different protection patterns at
different pH levels are highlighted in the black boxes.

Figure 2‐14 Partial sequence alignment conservation of amino acids 506‐537
(numbering based on human TfR) in the protease‐like domain of TfR/PSMA family. The
unique α‐helix (residues 492‐502) in PSMA is highlighted in the black box. The TfR
Trp528 is highlighted in the blue box. The diagram is generated using the BLASTP
program (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
pH‐Induced Conformational Change within TfR
TfR has different binding affinities to holo‐ and apoTf at different pH levels. Thus,
it is possible that TfR could undergo a pH‐induced conformational change that is
responsible for its different Tf binding properties. However, the lack of structural
information of both free TfR and the Tf/TfR complexes at acidic pH greatly limits our
understanding of the receptor binding mechanism. To get a detailed picture of how pH
mediates the conformational change within TfR to impact Tf binding properties and the
stabilities of different Tf/TfR complexes, we carefully examined the HDX data of TfR at
different pH levels (pH 7.5 exchanging for 30 seconds (“neutral” state of TfR) vs. pH 5.5
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exchanging for 10 minutes (“acidic” state of TfR) to offset the intrinsic exchange rate
(see Materials and Methods 2.2.5)). Any change observed between the “neutral” and
“acidic” states of TfR may be related to acid‐driven structure change/realignment that
impacts the stability of different Tf/TfR complexes in the endosome.
As shown in Figure 2‐15A, TfR exhibited similar protection patterns at pH 7.5 and
5.5, with the exception of two regions in the helical domain, [628‐636] and [702‐712]
(the differences in HDX% are 9.2% and ‐12.0%, respectively, with the threshold of
significance is ±8.2%). The peptide segment [628‐636], residing in the helix α2 and
locating near both the TfR/TfR dimer interface and the Tf binding region, gained
protection at pH 5.5 (Figure 2‐15C). In contrast, the other peptide segment [702‐712]
tended to be more flexible at lower pH level (Figure 2‐15D). It is a part of the loop
(residues 685‐710) that connects the helical domain to the rest of TfR (Figure 2‐15B).
Comparing the structures of TfR and PSMA, the analogous region of TfR segment [702‐
712] in PSMA has a six‐amino acid insertion and shows as a beta‐hairpin, termed the
glutarate sensor, that is unique to PSMA (Figure 2‐13 and Figure 2‐15E). This region
shows strong conservation among each subfamily but is family‐distinctive (Figure 2‐13).
The role of this glutarate sensor in PSMA is for substrate recognition and/or binding (95)
but unclear in TfR. In TfR, the loss of beta‐strands makes this region unstructured. It is
much shorter due to the deletions in TfR and unable to reach into the apical‐protease
domain interface, making the helical domain of TfR relatively flexible in solution. We
suggest the conformational change of the segment [702‐712] (as a part of the loop 685‐
710) in “acidic” state of TfR (became more flexible) is relevant vis‐à‐vis transduction of
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conformational changes between/within the protein domains that trigger a
rearrangement of the helical domain to dock apoTf at acidic pH. Specifically, lowering
the pH to 5.5, the increase in flexibility of the segment [702‐712] could be conveyed to
the loop Arg719‐Glu728 through the helix α5. The loop Arg719‐Glu728 contains an N‐
glycosylation site on Asn727 which is critical for Tf binding and the correct transport of
TfR back to the cell surface (169). Unfortunately, no data was collected for it which was
probably due to the presence of glycosylation. It has been reported that the
glycosylated form of protein is much less stable than the unglycosylated form as
lowering the pH (170). We propose that changing the pH from neutral to acidic, the loop
Arg719‐Glu728 becomes slightly more flexible and expanded in solution. The loop
Arg719‐Glu728 interacts with the helix α2 through salt bridges between Asp631 and
Glu634 in the helix α2 and Arg719 at neutral pH. At acidic pH, the movement of the loop
Arg719‐Glu728 could then form an additional salt bridge between Asp631 and Lys720
that stabilizes the helix α2 (Figure 2‐15B). Due to the critical position of the helix α2 in
the tertiary structure, connecting to both the helix α1 and α3 which have extensive
interactions with Tf, the change at the helix α2 may play as a switch that affects the
conformation/position of the rest of the helical domain (the helix α1 and/or α3) to make
the apoTf binding more favorable at acidic pH.
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Figure 2‐15 HDX comparison of TfR at different pH levels. (A) The deuterium uptake
difference of TfR colored to the structure (PDB: 1CX8) obtained following 30 seconds of
the exchange at pH 7.5 with those obtained following 10 minutes of the exchange at pH
5.5. Residues not observed in this work are colored in black. One TfR monomer is shown
in cartoon, while the other monomer is shown as surface. (B) Zoom‐in view of the area
highlighted in panel (A). The suggested interactions between the helix α2 and the loop
Arg719‐Glu728 after a pH‐induced conformational change are highlighted in yellow lines.
The mass spectra of the peptide segment [628‐636] and [702‐712] in the free TfR at
different pH levels are shown in (C) and (D), respectively. Peaks marked with a star (*) in
panel (D) represent the signal of the peptide segment [702‐712] exchanging in the
deuterium‐containing buffer at different pH levels. (E) The structure of PSMA (PDB:
2OOT) highlights the glutarate sensor.
Tf/TfR Binding Interfaces at Neutral and Acidic pH: Mechanism of Environmental
Regulation of TfR Binding Selectivity
The binding affinities between TfR and Tfs are pH‐sensitive, with the holoTf
being strongly favored at neutral pH and the apoTf favored at acidic pH, and the
presence of TfR can dramatically impact the iron release process from each lobe of Tf
under acidic condition (171). It is believed that this is achieved through some yet
unidentified adjustment of Tf/TfR binding interface in either Tf or TfR, or both
(70,172,173). However, any solid proof of this conjecture is still lacking due to the
unavailable crystal structure of either free TfR or the Tf/TfR complexes at acidic
condition and the low resolution of the currently available crystal structure of Fe2Tf/TfR
complex at neutral pH (72). To test the hypothesis according to what conformational
change within TfR that primarily affects the structure at the Tf/TfR interface region,
makes the interaction with apoTf more favorable at acidic pH and holoTf more favorable
at neutral pH and participates in the iron release in the endosome, we characterized the
changes at the Tf/TfR binding interface at both neutral and acidic pH.
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2.3.5.1

Characterizing Tf/TfR Binding Motif at Acidic pH and its Relation to Iron
Release from Tf
In general, the difference in deuterium incorporation in TfR between the holo‐

and apoTf/TfR complexes at pH 5.5 (correspond to the state before and after iron
release from Tf) was not significant, except for a few peptide segments in the helical
domain of TfR (highlighted in the circles in Figure 2‐16 with the threshold of significance
is ±6.7% and the positions of these peptide segments are shown in Figure 2‐17I),
suggesting these segments are involved in control iron release from Tf. More
importantly, all of them are located in/near the predicted Tf C1/TfR interface region
based on the structure of FeNTf/TfR complex. Since the presence of TfR can accelerate
iron release from the C‐lobe of Tf and only the C1 subdomain interacts with TfR, the
changes observed in HDX at the Tf C1/TfR interface region upon binding with different
forms of Tf here could provide valuable structural information on the characterization of
the specific binding sites between “acidic” state of TfR and the open and closed
conformations of Tf, helping us better understand the mechanism of iron release
process from the C‐lobe of Tf in the presence of TfR.
Detailed comparisons of the deuterium uptake levels for the peptide segments
at Tf C1/TfR interface region at pH 5.5 are shown in Figure 2‐18. Extra protection
afforded by apoTf to TfR was observed for two peptide segments, [621‐627] and [637‐
642], residing in the helix α1 and α3, respectively, but not in the holoTf/TfR complex,
suggesting these two segments contain contacts with apoTf but not with holoTf. The C‐
terminal peptide segment [747‐760] was also protected in the apoTf/TfR complex,
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compared to TfR alone. While in the holoTf/TfR complex, it was relatively protected
initially (30 seconds), and then began approaching to the exchange level as that in the
free TfR (became unprotected) during the time course, suggesting a weak binding at the
TfR C‐terminus in the holoTf/TfR complex. In comparison, the peptide segment [643‐649]
in the helix α3, contiguous with [637‐642], exhibited similar protection levels in the free
TfR and the apoTf/TfR complex but different protection levels between holo‐ and
apoTf/TfR complexes, suggesting this segment might be involved in holoTf binding. In
contrast, the peptide segment [628‐636] in the helix α2 did not show any difference in
all forms of the sample. Although the previous study (65) indicated the residue Arg629
in TfR interacts with Asn361 and Gly617 in Tf at neutral pH, conformational changes
within TfR helix α2 (CHAPTER 2.3.4) and/or Tf in response to the changes of the
surrounding environment cause these interactions no longer exist at acidic pH.
In summary, at pH 5.5, obvious protections were observed in the C‐terminal
region ([747‐760]), as well as the segments [621‐627] and [637‐642] when TfR was
bound to apoTf, while the segment [643‐649] were only protected in the holoTf/TfR
complex. These observations are consistent with the notion of both Trp641 and Phe760
in TfR are essential for apoTf binding at acidic pH which can form a hydrophobic patch
on the outside edge of the helical domain and interact with His349 and His350 in Tf to
stimulate iron release (70). However, after inspecting the crystal structure of FeNTf/TfR
(PDB: 3S9N), the distances between the Trp641‐Phe760 hydrophobic patch in TfR and
His349 and His350 in Tf (about 6‐13Å) are far more extended to form an interaction
(Figure 2‐19A). More likely, in order to build these interactions with apoTf at acidic pH, it
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requires a larger conformational rearrangement in TfR and/or Tf. Specifically, at pH 7.5,
the C‐terminal segment interacts with His349 (and His350) in Tf through both hydrogen
bonds and van der Waals (65). Once the holoTf/TfR complex enters the endosome, we
suggest within TfR, the pH‐induced conformational change at the helix α2 in the helical
domain performs as a switch and triggers position shifts on the helix α1 and/or α3, as
well as a possible compensatory movement by the helix α1 in the C1 subdomain of Tf
(the red arrows in Figure 2‐19B). The movements bring the TfR helix α3 close enough to
Tf to form strong cation‐π interactions between Trp641 and the C‐terminus (Phe760) in
TfR and the protonated His349 and His350 in Tf. In addition, these movements also
convert the interactions of Asp356, Glu357 and Ser359 in the helix α1 of Tf with Arg651,
Tyr643 and Arg646 in the TfR helix α3 into the new interactions with Arg623 and Asn626
in the TfR helix α1 to stabilize the apo‐ conformation.

Figure 2‐16 Plot of the different deuterium uptake levels following 2 minutes of the
exchange between the holo‐ and apoTf/TfR complexes at pH 5.5. The dashed lines
indicate the threshold of significant difference in HDX% (±6.7%). The peptic segments
showing noticeable differences before and after iron release are highlighted (I: [621‐
627], II: [637‐642], III: [643‐649], and IV: [747‐760]). The predicted Tf interaction regions
and the TfR dimer interface regions (based on the crystal structure of FeNTf/TfR (PDB:
3S9N)) are highlighted in black and blue, respectively. The region of each domain is color
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coded on the x‐axis, purple for the protease‐like domain, dark blue for the apical
domain, and green for the helical domain, respectively.

Figure 2‐17 Mapping of HDX protection data on the crystal structure of holo‐ (A‐C) and
apoTf/TfR complex (D‐F) following 30 seconds (top), 2 minutes (middle) and 10 minutes
(bottom) of deuterium exchange at pH 5.5. Color coding reflects the protection of
segments from highly protected (blue) to highly flexible (red). The differences in the
percentage of exchange (holo –apo) are shown in G‐I, following the same exchange time
course. Residues not observed in this work are colored in white in structures A‐F and are
colored in black in structures G‐I. The Tf is shown in ribbon with the N‐lobe of Tf is
colored in pink and the C1 subdomain of Tf is colored in cyan. One monomer in the
homodimer of the Tf/TfR complex is shown in cartoon, while the other is shown as
surface. The four segments (I: [621‐627], II: [637‐642], III: [643‐649], and IV: [747‐760])
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showing noticeable differences before and after iron release are labeled in the panel I
(with the threshold of significant difference in HDX% is ±6.7%).

Figure 2‐18 (A) The plots of deuterium uptake levels of the five peptide segments
located at the Tf C1/TfR binding motif in the free TfR (black), as well as binding with
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holoTf (red) and apoTf (blue) at pH 5.5. The Tf molecule has been removed with the
exceptions of residues 347‐366 (Tf α1) and 614‐620 (cyan). The helical domain of TfR is
colored in gray. (B) The m/z spectra of the five peptide segments in different forms of
protein as described in panel (A). The non‐exchanged control and the fully deuterated
spectra for each peptide are colored in black and gray at the bottom, respectively.

Figure 2‐19 (A) Structure of the Tf C1/TfR binding motif in FeNTf/TfR (PDB: 3S9N)
highlights the distances between the Trp641‐Phe760 hydrophobic patch in TfR and His
349 and His350 in FeNTf (~6‐13Å) at neutral pH by yellow dashed lines. Several residues
at the interface of Tf C1/TfR are shown as sticks. (B) Schematic depicts the movements
(red arrows) of the helical domain of TfR (gray) as well as the Tf helix α1 (cyan) in the
endosomal pH which stabilize apoTf binding.
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2.3.5.2

Tf/TfR Binding Motif at Neutral pH and its Relation to Tf Binding Affinity and
Dissociation of apoTf from TfR
At neutral pH, TfR is able to weakly bind apoTf but apoTf dissociates more

rapidly than holoTf. To characterize the changes within TfR that lead to its different Tf
binding affinities and dissociation of apoTf from TfR, we compared the protection levels
between holoTf/TfR and apoTf/TfR complexes at pH 7.5 (Figure 2‐20). Obvious
differences were observed at the Tf C1/TfR interface region in the helical domain, with
the threshold of significance for exchanging 30 sec, 2 min and 10min is ±9.5%, ±7.9%
and ±8.4%, respectively. Some peptide segments located at the protease‐like and the
apical domains, near/at the interdomain cleft region, also gained protection in the
apoTf/TfR complex (colored in red in Figure 2‐20G‐I) due to the observations of the
bimodal isotopic distributions (discussed in CHAPTER 2.3.3.3 and 2.3.3.4).
Figure 2‐21 shows the comparison of the protection levels of the peptide
segments located at the Tf C1/TfR interface region at pH 7.5 which correspond to the
binding interface between “neutral” state of TfR and the open and closed conformations
of Tf. The segment [637‐642] in the TfR helix α3 was only protected in apoTf/TfR,
whereas its neighboring segment [643‐649] was only protected in holoTf/TfR. Both the
C‐terminus and the segment [621‐627] in the TfR helix α1 gained protection in both
holo‐ and apoTf/TfR complexes. Although both C‐terminus and the segment [637‐642]
were still protected in the apoTf/TfR when increasing the pH from 5.5 to 7.5 (Figure 2‐18
and Figure 2‐21), we suggest the interactions between Trp641/Phe760 in TfR and
His349/His350 in Tf weaken at pH 7.5 due to the deprotonation of His residues that
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convert the strong cation‐π interactions (between the protonated His and aromatic
amino acids) to the weak π‐π stacking interactions (between the neutral His and
aromatic amino acids) (174), thus lead to the dissociation of apoTf from TfR at neutral
pH. In addition, the segment [637‐642] was only protected in the apoTf/TfR at both pH
7.5 and 5.5, not in holoTf/TfR (Figure 2‐18 and Figure 2‐21). We propose that the
interaction between Trp641 in TfR and His349 in Tf is essential for apoTf binding and
stabilizing the open conformation of the Tf C‐lobe at both acidic and neutral pH. In
contrast, the segment [643‐649] was protected only in the holoTf/TfR at both pH 7.5
and 5.5 (Figure 2‐18 and Figure 2‐21). This segment contains the RGD binding sequence
(Arg646‐Gly647‐Asp648) (175,176) which is conserved in TfR in mammals, birds, reptiles
and amphibians (50). We suggest this RGD sequence in TfR is critical for holoTf binding,
but not apoTf. At pH 7.5, comparing with the data at pH 5.5, extra protections in TfR
upon holoTf binding were observed at the segment [621‐627] and the C‐terminus, which
were contributed by the contacts between Val622, Arg623, Asn626, Glu759 in TfR and
Val360, Val363 and Asn361, His349 in Tf, respectively. We propose these new contacts
strengthen the interaction between TfR and holoTf and are responsible for its high
holoTf binding affinity at neutral pH. In spite of the predict interactions of Arg629 in TfR
with Asn361 and Gly617 in Tf in the FeNTf/TfR model (65), the segment [628‐636] in the
TfR helix α2 showed no change in protection in both complexes under experimental
condition. These interactions in solution might be too weak to be captured by HDX.
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Figure 2‐20 Mapping of HDX protection data on the crystal structure of holo‐ (A‐C) and
apoTf/TfR complex (D‐F) following 30 seconds (top), 2 minutes (middle) and 10 minutes
(bottom) of deuterium exchange at pH 7.5. Color coding reflects the protection of
segments from highly protected (blue) to highly flexible (red). The differences in the
percentage of exchange (holo –apo) are shown in G‐I, following the same exchange time
course. Residues not observed in this work are colored in white in structures A‐F and are
colored in black in structures G‐I. The Tf is shown in ribbon with the N‐lobe of Tf is
colored in pink and the C1 subdomain of Tf is colored in cyan. One monomer in the
homodimer of the Tf/TfR complex is shown in cartoon, while the other is shown as
surface.
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Figure 2‐21 (A) The plots of deuterium uptake levels of the five peptide segments
located at the Tf C1/TfR binding motif in the free TfR (black), as well as binding with
holoTf (red) and apoTf (blue) at pH 7.5. The Tf molecule has been removed with the
exceptions of residues 347‐366 in Tf α1 and 614‐620 (cyan). The helical domain of TfR is
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colored in gray. (B) The m/z spectra of the five peptide segments in different forms of
protein as described in panel (A). The non‐exchanged control and the fully deuterated
spectra for each peptide are colored in black and gray at the bottom, respectively.
Conclusion
Tf/TfR pathway is one of the primary routes for most mammalian cells to uptake
circulating iron in plasma. Although the structure and dynamics of Tf and the roles of Tf
in iron homeostasis are fairly well characterized (177‐180), lacking the structures of TfR
and Tf/TfR complexes, especially under the acidic condition, makes the studies of the
Tf/TfR binding properties throughout receptor‐mediated endocytosis even harder. In
the present work, HDX MS is used to monitor the changes in conformational dynamics
within TfR upon different forms of Tf binding at both pH 7.5 and 5.5. The proposed
Tf/TfR binding mechanism is displayed in Figure 2‐22. The changes in TfR afforded by Tf
are of significance. Specifically, 1) several peptide segments located at the TfR/TfR dimer
interface region gained protection upon holoTf binding at pH 7.5, indicating binding with
holoTf results in a rotation at the TfR/TfR dimer interface that brings the two monomers
into proximity contributes to the stabilization of the holoTf/TfR complex (Figure 2‐22
III). 2) The observations of bimodal isotopic distributions of several peptide segments
located at the interdomain cleft in the free TfR but not in Tf/TfR complexes suggest
binding with Tf could induce the structural allosteric effect which reduces the flexibility
of the apical domain of TfR in the Tf/TfR complex, making the interdomain cleft in a
relatively open position (Figure 2‐22 III). 3) The comparison between “neutral” and
“acidic” states of TfR reveals the pH‐induced conformational changes at the helical
domain of TfR which are considered to be the key steps in Tf binding selectivity.
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Lowering the pH to 5.5, the increase in flexibility of the loop 702‐712 makes the helical
domain relatively flexible in solution and the conformational change at the helix α2
(became more stable) plays as a switch that 4) triggers the position shifts on the helix α1
and α3 to stabilize the C‐lobe of Tf in the open conformation by strengthening the apoTf
binding through strong cation‐π interactions (protonated His349/His350 in Tf with both
the TfR C‐terminus and Trp641 in the helix α3) and salt bridge or amide bridge
interactions (Asp356 and Glu357 in Tf with Arg623 and Asn626 in TfR helix α1) (Figure
2‐22 III). In addition, 5) the conformational change at Trp528 at pH 5.5 could influence
the position of the bridge in Tf by forming a cation‐π interaction with Lys340 in Tf
whereby further accommodates Tf clefts opening (Figure 2‐22 III). 6) By comparing HD
exchange levels at the Tf C1/TfR interface region in different Tf/TfR complexes, we were
able to capture conformational changes in TfR upon binding with different forms of Tf,
allowing a detailed description of the site‐specific interactions between TfR and the C‐
lobe of holo‐ and apoTf that account for its different Tf binding affinities. We propose
the interaction between Trp641 in TfR and His349 in Tf is essential for apoTf binding and
stabilizing the open conformation of the Tf C‐lobe, while the RGD binding sequence
(Arg646‐Gly647‐Asp648) in TfR is critical for holoTf binding. At pH 7.5, the interactions
between Trp641/Phe760 in TfR and His349/His350 in Tf weaken due to the
deprotonation of His, leading to the dissociation of apoTf from TfR. Extra protection in
TfR upon holoTf binding observed at the segment [621‐627] and the C‐terminus
contributes to its high holoTf binding affinity at neutral pH.
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Altogether, our results extend the characterization of Tf/TfR interactions to both
neutral and endosomal pH and provide, for the first time, the structural dynamics
information of the Tf/TfR system under different conditions that mimic the stages
encountered during endocytosis. Such a map greatly benefits our understanding of the
molecular mechanism of modulation of TfR binding selectivity by pH and how TfR
facilitates iron release from the C‐lobe of Tf in the endosome, especially the structure
information of neither free TfR nor the Tf/TfR complexes at acidic condition is available.
Although this work is more focused on investigating the conformation and dynamics of
TfR, following experiments are planned to characterize the changes on Tf in the
different forms of Tf/TfR complex at neutral and acidic pH to better understand the
Tf/TfR binding properties and the roles of iron release in the presence of TfR.
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Figure 2‐22 Schematic diagram illustrating the Tf/TfR interactions under different
conditions. The specific binding site between “neutral” state of TfR and the C‐lobe of
holoTf at pH 7.5 is highlighted in orange in (II). The specific binding site between “acidic”
state of TfR and the C‐lobe of apoTf at pH 5.5 is highlighted in magenta in (III). The pH‐
induced conformational change at the helical domain of TfR is highlighted as star symbol
in (III). H: TfR helical domain; A: TfR apical domain; P: TfR protease‐like domain; C: Tf C‐
lobe; N: Tf N‐lobe. Only one Tf molecule in Tf/TfR complex is shown in the schematic.
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EVALUATION OF NONFERROUS METALS AS POTENTIAL IN VIVO TRACERS OF
TRANSFERRIN‐BASED THERAPEUTICS
This chapter was published in Journal of The American Society for Mass
Spectrometry 27(2) (2016): 211‐219.
Abstract Transferrin (Tf) is a promising candidate for targeted drug delivery. While
development of such products is impossible without the ability to monitor
biodistribution of Tf‐drug conjugates in tissues and reliable measurements of their levels
in blood and other biological fluids, the presence of very abundant endogenous Tf
presents a significant impediment to such efforts. Several noncognate metals have been
evaluated in this work as possible tracers of exogenous transferrin in complex biological
matrices using inductively coupled plasma mass spectrometry (ICP MS) as a detection
tool. Placing Ni(II) on a His‐tag of recombinant Tf resulted in formation of a marginally
stable protein‐metal complex, which readily transfers the metal to ubiquitous
physiological scavengers, such as serum albumin. An alternative strategy targeted iron‐
binding pockets of Tf, where cognate Fe(III) was replaced by metal ions known to bind
this protein. Both Ga(III) and In(III) were evaluated, with the latter being vastly superior
as a tracer (stronger binding to Tf unaffected by the presence of metal scavengers and
the retained ability to associate with Tf receptor). Spiking serum with indium‐loaded Tf
followed by ICP MS detection demonstrated that protein quantities as low as 0.04 nM
can be readily detected in animal blood. Combining laser ablation with ICP MS detection
allows distribution of exogenous Tf to be mapped within animal tissue cross‐sections
with spatial resolution exceeding 100 μm. The method can be readily extended to a
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range of other therapeutics where metalloproteins are used as either carriers or
payloads.
Keywords: ICP MS, Laser ablation, Tissue imaging, Targeted drug delivery, Stable
isotopes
Introduction
A very large number of potent drug candidates showing superior characteristics
vis‐à‐vis interactions with their intended therapeutic targets in vitro nonetheless fail
clinical trials because of their inability to specifically target the intended site of action.
Escalating the drug dosage remains a standard remedy for this problem, but
therapeutically effective doses may (and frequently do) exceed safety limits and, in
extreme cases, may be fatal for the host organism. More specific delivery can be
achieved in some cases by taking advantage of certain anatomical features of the
targeted sites (e.g., leaky vasculature and poor drainage in many tumors, which result in
preferential retention of macromolecules via enhanced permeation and retention, EPR).
The possibility to exploit the EPR phenomenon generated significant enthusiasm in the
field of oncology (181) and has already led to the introduction of new anti‐cancer
medicines (e.g., albumin‐bound paclitaxel (182)). Unfortunately, the initial excitement
was tempered by the limited specificity of the EPR effect (limited by the lack of cellular
specificity, low vascular density, and early release of active agents (183)); tumor‐to‐
tumor variability also limits EPR usefulness (184). An orthogonal approach to drug
delivery that is enjoying popularity in areas as diverse as oncology, neurodegenerative
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diseases, rare genetic disorders, and regenerative medicine takes advantage of existing
transport networks within the organism. An example of a promising drug delivery
system where opportunities to improve routing are frequently overlooked is Tf, an 80
kDa iron glycoprotein, the primary function of which is the delivery of iron to cells. It is
one of very few plasma proteins that gain cellular entry by the process of receptor‐
mediated endocytosis (178), a fact that has long attracted attention of the drug design
community (17,23,32,185).
For example, malignant cells have dramatically elevated iron demands to sustain
their uncontrolled growth and overexpress TfR, making Tf an attractive candidate for
the selective delivery of cytotoxic agents to cancer cells, where cytotoxins could be
either small molecule drugs chemically attached to Tf surface (8,17,20), macromolecules
(such as Tf‐diphtheria toxin conjugate TransMID (186)), or nano‐objects, such as Tf‐
functionalized nanoparticles for siRNA delivery (187). Above and beyond internalization
via receptor‐mediated endocytosis, Tf can traverse polar cells in the process of
transcytosis (188), allowing it to cross physiological barriers (such as BBB (189) and the
intestinal epithelial barrier (190)). Efforts aiming at exploitation of this unique trait for
the purpose of targeted drug delivery are also underway, with the ultimate goal of
developing therapeutic agents that can reach targets shielded from the vast majority of
existing drugs (191,192). We have recently started exploring a possibility of conjugating
a bacteriolytic enzyme to Tf for targeting microbial infections in the central nervous
system (34,35).
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Among the many challenges faced by development of such products is difficulty
associated with the need to obtain accurate and quantitative data on biodistribution of
exogenous (administered) Tf and/or Tf‐based therapeutics on the background of very
abundant and structurally similar (if not identical) endogenous Tf. Indeed, Tf
concentration in serum of healthy human subjects ranges between 25 and 50 μM (193),
at least two orders of magnitude above the serum concentration of exogenous Tf even if
highly concentrated preparations are used for injection. Although radiolabeling (e.g.,
using

125

I) can be used to detect such levels of exogenous Tf (194), it requires protein

modification, which may impact its receptor binding and, therefore, affect the
biodistribution. Furthermore, since the endogenous Tf is expected in most relevant
cases to be structurally very similar (if not identical) to the exogenous protein, this not
only rules out the use of ELISA as a detection/quantitation tool (due to likely cross‐
reactivity), but also makes the use of many proteomics‐inspired tools (e.g., using

18

O‐

labeling of proteolytic fragments (195) or entire protein (196)) highly problematic.
Although in our previous work we were able to detect exogenous Tf in biological fluids
using the 18O‐labeling strategy, we had to rely on the affinity purification step prior to
MS detection taking advantage of the His‐tag segment of the recombinant Tf (197).
Presence of the abundant and structurally similar endogenous Tf in tissues would also
make it impossible to use traditional MALDI MS imaging approach for localization
studies of exogenous Tf and Tf‐based drugs in tissues, which typically relies on in situ
proteolysis of proteins followed by detection of fragment peptides (198).
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An alternative approach to detection and quantitation of exogenous proteins in
complex biological matrices relies on placing metal tags on proteins followed by their
detection with ICP MS (199), although most of those applications were limited to model
studies currently. ICP MS is a sensitive technique for measuring metal‐ and metalloid‐
containing compounds (125), and in the absence of interferences from ubiquitous
metals and plasma‐related ions it can allow the limits of detection to be achieved at low
fmol level (126,127). However, covalent modification of the protein surface with metal‐
containing tags, (e.g., p‐hydroxymercuribenzoic acid (200) or reactive metal chelates
such as activated DTPA (201) and DOTA (202), which form strong complexes with
multiple lanthanides (203)), is likely to exert at least some influence on protein
interactions with its physiological partners. In the case of Tf and/or Tf‐based
therapeutics, covalent modification is likely to interfere with the receptor binding
process, a key step in both endocytosis and transcytosis, thereby inevitably altering their
trafficking patterns and rendering the biodistribution data meaningless.
Tf contains a “cognate” metal tag (iron), some isotopes of which can be detected
by ICP MS with very high sensitivity, but it can hardly be used as a specific Tf tracer
because of its ubiquity in all biological fluids (mostly from hemoglobin and endogenous
Tf) and tissues (ferritin, myoglobin, cytochromes, etc.). While Tf is known to bind a wide
range of other metals (204), the affinities vary greatly (102), and a good Tf tracer must
be selected carefully. In addition to the iron binding site, we also explore the utility of
the His‐tag, a histidine‐rich segment of the recombinant Tf (as well as many other
recombinant proteins) as a potential site for metal tagging. In this study, we limited the
99

scope of inquiry by examining two noncognate metals (indium and gallium), the
interaction of which with Tf at the iron‐binding sites is well‐documented (102), and
nickel as ametal targeting the His‐tag segment of the protein (205). Four criteria are
used to select acceptable non‐ferric Tf tracers with ICP MS detection: (1) the metal
should form a stable complex with the protein, (2) the metal should not be removed
from Tf by ubiquitous scavengers, such as serum albumin or iron‐free endogenous Tf, (3)
the presence of the metal should not affect the receptor binding properties of the
protein, and (4) minimal interferences from ubiquitous metals and plasma‐generated
ions (such as Ar+, ArO+, CaOH+, etc.).
Materials and Methods
Preparation and Characterization of Tf Tagged with Nonferrous Metals
A diferric form of human serum transferrin (Fe2Tf) (Intergen, Purchase, NY, USA)
was converted to the apo‐form (apo‐Tf) by washing it with 1 mM EDTA in 3% (v/v)
CH3CO2H, followed by buffer exchange to 50 mM HEPES buffer at pH 7.5. Indium and
gallium were purchased from Alfa Aesar (Ward Hill, MA, USA). In‐ and Ga‐tagged Tf were
produced by incubating apoTf with metal∙nitrilotriacetate (NTA) complexes in 100 mM
NH4HCO3 and 50 mM HEPES buffer at room temperature for 1 hour followed by buffer
exchange to 150 mM ammonium acetate, pH 7.5. The extent of protein tagging was
determined by native ESI MS using a SolariX Fourier transform ion cyclotron resonance
(FT ICR) mass spectrometer (Bruker Daltonics, Billerica, MA, USA). The possibility of
metal exchange between In‐ and Ga‐tagged Tf and apo‐Tf, as well as the receptor‐
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binding by Tf substituted with nonferrous metals, was examined by native ESI MS using
a QStar XL (AB Sciex, Toronto, Canada) hybrid quadrupole/time‐of‐flight mass
spectrometer equipped with a standard ESI source.
Recombinant human Fe2Tf containing an N‐terminal His‐tag was generously
provided by Professor Anne B. Mason (University of Vermont College of Medicine), and
the nickel‐tagged form of this protein was produced by incubating it with significant
molar excess of NiSO4 in 20 mM ammonium acetate at pH 7.5. The extent of Fe2Tf
tagging with Ni2+ was determined by native ESI MS using a SolariX FT ICR mass
spectrometer (vide supra). Unlike most other glycoproteins, Tf exhibits surprisingly little
heterogeneity (see Figure 3‐6 in Supplementary Material), which makes the analysis of
metal‐binding measurements carried out by native ESI MS relatively straightforward.
The efficiency of nickel transfer to albumin was determined by incubating the Ni‐tagged
protein with bovine serum albumin (Calbiochem, La Jolla, CA, USA) prior to the ESI MS
analysis.
ICP MS
Limits of detection of In‐tagged Tf (In2Tf) by ICP MS were determined by spiking
1 mL of bovine serum (Equitech‐Bio, Inc., Kerrville, TX, USA) with a measured amount of
In2Tf, followed by an overnight digestion using 2 mL of freshly prepared HNO3/H2O2
mixture (3:1, v:v). Rhodium (Inorganic Ventures, Christiansburg, VA, USA) was used as
an internal standard and was added to the serum prior to digestion. The digested
samples were diluted with deionized water to a final volume of 20 mL. A series of
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indium standard solutions (5, 2, 1, 0.5, 0.2, 0.1, 0.05, 0.02, 0.01, and 0 ppb) containing
10% HNO3/H2O2 and spiked with internal standard were prepared before each
experiment. All ICP MS measurements were carried out using a NexION 300X ICP mass
spectrometer (PerkinElmer, Waltham, MA, USA).
Animal Models
Experiments were carried out at the animal facilities of the University of
Massachusetts, Amherst, on 10‐week‐old male Wistar rats purchased from Charles River
Laboratories (Wilmington, MA, USA). All In2Tf samples were buffer‐exchanged into 100
mM sterilized PBS buffer solution prior to injections. Rats were euthanized by CO2
overdose 24 hours after the intravenous injection of 7.5 mg/kg dose of body weight of
In2Tf. Blood samples were collected in heparin coated tube to prevent coagulation.
Organs of interest were harvested, rinsed in PBS, dried, weighed, and stored in a –80°C
freezer.
Imaging LA‐ICP MS
Organs of rats were embedded in Tissue‐Tek O.C.T. compound (Sakura Finetek
USA, Torrance, CA) and cryocut at –20°C into slices of 20 μm thickness with a LEICA
CM1850 cryostat (Leica Microsystems GmbH, Wetzlar, Germany). The slices were placed
on regular glass slides and air dried. Experiments were conducted with a CETAC LSX‐213
G2 laser ablation system (Lincoln, NE, USA) coupled to the NexION 300X ICP mass
spectrometer (vide supra). LA unit was synchronized with the ICP MS in external
triggering mode. Organ sections were inserted into the cell and ablated line by line.
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Elemental images were reconstructed using ImageJ, an open source image generator
software (http://rsbweb.nih.gov/ij/), following the extraction and compilation of
individual element list of pixels from raw data files, each of which was acquired from a
single ablated line containing signal intensity values for all metals measured (e.g., 57Fe
and 115In).
Results and Discussion
Evaluation of Nickel as a Tracer of Recombinant Tf and Tf‐Based Products
The recombinant form of Tf used in our work had an N‐terminal His‐tag, a short
peptide containing a hexahistidine segment, which is frequently inserted into the wild‐
type protein sequence to facilitate its purification on Ni columns. Since the His‐tag has
high affinity to Ni2+ ions and at the same time does not participate in Tf interaction with
its receptor, it might be considered as a possible location for placing a metal tag for ICP
MS detection. Indeed, saturation of Tf solution with molar excess of NiSO4 resulted in
attachment of at least one metal ion to each Tf molecule, as evidenced by the
disappearance of the Ni‐free protein signal from the native ESI mass spectrum and
appearance of protein ions, masses of which are consistent with formation of Ni adducts
(Figure 3‐1). Importantly, binding with nickel did not lead to a conformational change, as
no high charge density ions (below m/z 3,000) were detected.
However, the ability of recombinant Tf to bind Ni2+ ions does not guarantee that
this metal could be a reliable tracer of this protein in biological samples: should this
metal be removed from Tf while in circulation by various scavengers, all information on
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Tf distribution obtained by tracing Ni as a tracer using ICP MS would be meaningless.
The stability of the Ni adducts of Fe2Tf was evaluated by incubating Ni‐saturated Fe2Tf
with equal amount of albumin, the principal nickel binding protein in vivo (206). Native
ESI MS spectra acquired post‐incubation provide unequivocal evidence that the majority
of Ni2+ ions are readily removed from the His‐Tag of recombinant Tf by albumin (Figure
3‐1 inset, top trace), indicating that this metal cannot be used as a reliable tracer of Tf in
vivo.

Figure 3‐1 ESI mass spectrum of recombinant iron‐saturated Tf incubated with NiSO4.
The inset shows ESI mass spectra of Tf before (red trace) and after (207) incubation with
NiSO4. The top trace shows the result of adding albumin to the solution of Tf incubated
with NiSO4. All mass spectra were acquired at near‐physiological conditions (pH 7.5, 20
mM ammonium acetate). Only ion peaks at charge state +20 are shown for clarity.
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Evaluation of Nonferrous Metals Associating with the Protein at the Iron Binding
Sites: Gallium and Indium
Unlike nickel, which readily binds to iron‐saturated Tf at the His‐tag segment, a
variety of metals can associate with the apo‐form of Tf at the iron‐binding sites (204).
Indium and gallium in particular are known to have significant Tf affinity comparable to
iron (204), and endogenous Tf has been implicated in transporting radioactive isotopes
of these metals used in medicine as imaging agents (25). Although many other metals
can form stable complexes with Tf, the significant difference in their ionic radii and that
of Fe3+ results in significant distortions of the closed conformation of Tf (102,208), which
is likely to have a pronounced influence on its receptor binding properties. Since our
goal here is to design tracers of Tf and Tf‐based therapeutics that would adequately
reflect their biodistribution, we limited our search to In3+ and Ga3+ as their physical
characteristics are sufficiently close to Fe3+ and, therefore, are less likely to alter the
receptor binding properties. Preparation of In‐saturated Tf at neutral pH results in
formation of a complex where association of In3+ with each lobe of the protein is also
accompanied by binding of a synergistic ion (CO32‐), mirroring the Fe3+ binding to this
protein. Contrary to this, binding of only a single Ga3+ ion to Tf (accompanied by the
synergistic anion) was observed under the identical conditions when Tf solution was
saturated with gallium salt. While earlier spectroscopic work provided evidence of Ga/Tf
complex formation with 2:1 stoichiometry (209,210), our results are consistent with the
previous studies of Ga/Tf complexes using native ESI MS, where only 1:1 complexes
were observed (102).
105

It may be argued that the absence of Ga2Tf species in native ESI mass spectra
could be a consequence of the failure of the metal binding to trigger cleft closure in one
of the Tf lobes (which is likely to diminish the protein/metal complex stability in the gas
phase, as is the case for Bi/Tf complex (102)). However, even if this is the case, and the
Ga2Tf species are indeed formed in solution but cannot be observed by native ESI MS
because one of the protein lobes remains in the open conformation (characteristic of
either the apo‐form of Tf, or the holo‐form of this protein at endosomal pH (211)), the
receptor binding characteristics of such putative Ga2Tf species would deviate from that
of Fe2Tf species, which makes Ga hardly suitable as a Tf tracer. Lastly, the GaxTf species
are unstable vis‐à‐vis metal replacement in the presence of ferric ion stabilized by low‐
molecular weight chelators: 1 hour incubation of Ga‐saturated Tf in Fe∙NTA solution
(with 10 times molar excess of Fe∙NTA) results in complete displacement of Ga3+ ions
and formation of diferric transferring, Fe2Tf (Figure 3‐2A). Therefore, should Ga‐labeled
Tf or Tf‐based therapeutic product be exposed to a pool of low‐molecular weight iron
post‐administration, there is a high likelihood that all metal labels will be lost, making it
impossible to trace the exogenous Tf using ICP MS‐based methods of detection.
Unlike gallium, indium shows vastly improved characteristics vis‐à‐vis Tf binding.
First, a dimetal form of indium‐saturated Tf (In2Tf) can be readily prepared with no
traces of apo‐Tf or In1Tf. Importantly, indium‐saturated Tf also exhibits markedly
improved stability when exposed to a pool of low‐molecular weight iron in vitro: one of
the In3+ ions remains to be bound to the protein even after 1 hour incubation of In2Tf in
solution of Fe∙NTA (10 times molar excess of the latter) with no sign of formation of the
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diferric Tf (Figure 3‐2B). Lastly, In2Tf is still capable of binding to transferrin receptor
(TfR) with high affinity, as is evident from the mass spectrum of the In2Tf/TfR mixture
acquired under near‐native conditions (Figure 3‐3). The only two ionic species present in
solution correspond to the free protein (which was present in slight excess) and its 2:1
complex with the receptor with no detectable signal corresponding to either free
receptor or 1:1 In2Tf/TfR complex.
While the ability of Tf to retain at least one bound In3+ ion even in the presence
of a large pool of low‐molecular weight iron is critical for the ability to track metal‐
labeled Tf in biological fluids and tissues, exchange of even a single In3+ ion from In2Tf
for ferric ion may create a pool of low‐molecular weight indium (not associated with Tf),
leading to false‐positive signals if indium is used as a Tf reporter. Although one might
expect that low‐molecular weight indium should be removed from circulation very
effectively by passing through the glomerular filters (in which case no false‐positive
signal would be generated), the circulation lifetime of indium not associated with Tf
might be significantly increased as a result of binding to scavenger proteins (such as
albumin), which would make quick passage through kidneys unlikely. In order to find
ways to increase the stability of In2Tf, we explored the utility of oxalate as an alternative
synergistic anion. Oxalate has been shown in the past to increase iron affinity of Tf to a
very significant extent (55,101,212), although its influence on stabilizing Tf complexes
with nonferric metals remains unknown. We investigated the ability of oxalate to “lock”
In3+ within Tf and prevent its exchange with low‐molecular weight iron by preparing
In2Tf in which both carbonates acting as synergistic anions were replaced with oxalate
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anions (see the Materials and Methods section for detail). The resulting complex
(In3+C2O42‐)2Tf was found to be remarkably stable with respect to metal retention,
showing no signs of indium‐to‐iron exchange after 1 hour incubation in a pool of low‐
molecular weight iron (Figure 3‐2C).

Figure 3‐2 Replacement of noncognate metals from Tf by iron: native ESI mass spectra
of Ga‐ (A) and In‐saturated Tf (B) incubated with Fe∙NTA. Only protein ion peaks at
charge state +20 are shown for clarity (gray traces show reference ion peaks of apo‐Tf).
The effect of replacing carbonate with oxalate as a synergistic anion on metal exchange
is shown in (C): In2Tf ions (charge state +20) in native ESI mass spectra of In‐saturated Tf
before (gray) and after incubation with Fe∙NTA (207).
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Figure 3‐3 Nano‐ESI mass spectrum of a mixture of In2Tf (6 µM) and TfR (3 µM) in 150
mM ammonium acetate at pH 7.5. The gray trace shows the reference spectrum of TfR
(acquired in the absence of Tf). Inset show the ionic signal representing the excess of
free In2Tf in solution.
Evaluation of Indium as a Tf Tracer in Biological Samples
Since indium has shown favorable characteristics vis‐à‐vis Tf binding and
preserving the receptor recognition properties of this protein, it has been investigated
as a tracer of exogenous Tf in biological samples both in vitro and in vivo. Possible matrix
effects were evaluated and the limit of detection was determined by spiking the
commercial bovine serum samples with small amounts of In2Tf solution in 150 mM
ammonium acetate, and comparing ICP MS spectra of these samples with the blank
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indium‐free commercial serum (spiked with 150 mM ammonium acetate solution
containing no In‐labeled protein). Indium has two stable isotopes (113In and

115

In), and

the only two metals that can potentially interfere with indium in ICP MS are cadmium
and tin. While none of these metals is expected to occur naturally in mammals, heavy
metals are frequently present in solvents and reagents (e.g., traces of tin may originate
from using stannous chloride SnCl2, a popular pre‐reducing agent, in manufacturing
commercial reagents used for processing biological samples prior to ICP MS analysis).
Indeed, a scan of m/z region 50 – 150 by ICP MS reveals a surprising wealth of elements
that were not necessarily expected to be detected in serum (Figure 3‐4A). Fortunately,
tin was found to be the only possible interfering element contributing very low
abundance isotopes to ionic signal at m/z 113 and 115. The origin of tin was traced to
the reagent‐grade hydrogen peroxide used for sample digestion (see Figure 3‐7 in
Supplementary Material for more detail), and it might be possible to eliminate this
interfering species from the ICP mass spectra altogether by selecting a higher‐quality
supplier of this reagent. Short of complete elimination of tin from the reagents, a
correction to the intensities of 113In and 115In can be readily made based on the known
abundance distribution of tin isotopes and the intensity of 116Sn,
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Sn, and other high‐

abundance tin isotopes in the ICP mass spectrum.
The signal for the most abundant indium isotope (115In) was clearly discernible in
the ICP mass spectrum of In2Tf‐spiked commercial serum sample where the final
concentration of indium was as low as 0.01 ppb (corresponding to 0.04 nM protein
concentration). A calibration curve for indium in serum constructed using rhodium as an
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internal standard (Figure 3‐4B) shows excellent linearity (R2 > 0.99) up to 5 ppb,
suggesting that In‐labeling can be used for sensitive detection and quantitation of
exogenous Tf and Tf‐based therapeutics in biological fluids and tissue homogenates.
Measuring indium concentration in blood, cerebrospinal fluid, and other
biological fluids following administration of Tf‐based therapeutics labeled with this
metal will be invaluable for obtaining reliable pharmacokinetic profiles of these protein
drugs. However, a detailed picture of biodistribution of Tf‐based therapeutics cannot be
reconstructed from the average concentrations of indium in tissue homogenates, where
all information on uneven distribution of the protein therapeutic across organ tissues
would be lost during the homogenization process. However, biodistribution patterns of
metals in organ cross‐sections can be obtained by combining ICP MS with laser ablation
(LA) (145), a technique that emerged in the past several years as a powerful tool to
probe distribution of biometals in various tissues (213). In order to assess the feasibility
of using LA‐ICP MS as a means of obtaining biodistribution patterns of Tf‐based
therapeutics in tissues, a metal distribution map was generated for a cross‐section of rat
spleen harvested twenty‐four hours after the injection of 2.5 mg of In2Tf. The medium‐
resolution distribution maps of iron (57Fe) and indium (115In) differ significantly in
absolute intensities, but the distribution patterns are very similar (Figure 3‐5),
suggesting that the sensitivity provided by LA‐ICP MS is adequate for mapping
biodistribution of Tf‐based therapeutics under clinically relevant conditions.
While detection and quantitation of proteins (including biopharmaceuticals) in
biological fluids can be carried out using commonly accepted approaches relying on
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introducing isotopic labels (e.g.,

18

O) either at the peptide (195) or the whole protein

level (196), application of these procedures to Tf‐based therapeutics is problematic
because of the presence of very abundant endogenous protein, the amino acid
sequence of which is very similar if not identical to that of the exogenous Tf. Therefore,
the ability to selectively detect and quantitate exogenous protein will hinge on the
ability to detect a proteolytic fragment unique to that protein, but absent from
endogenous Tf. An alternative strategy would take advantage of a non‐native segment
within the recombinantly produced exogenous protein (such as a His‐tag) to afford
selective capture of that protein (197). However, even in these circumstances, we have
found that the sensitivity afforded by ICP MS measurements of In2Tf exceeds that of the
commonly accepted techniques combining 18O labeling and LC/MS detection by at least
factor of three.
The advantages provided by indium labeling and ICP MS detection are even more
significant when it comes to measuring biodistribution patterns of Tf‐based
biopharmaceuticals. While molecular imaging with MALDI MS (214) can produce protein
distribution patterns in tissue cross‐sections, the size of Tf places it outside of the mass
range amenable to direct detection with MALDI TOF MS, and requires in situ digestion
to be carried out prior to imaging (215). The very low levels of exogenous Tf in tissues
under clinically relevant conditions and the presence of abundant endogenous Tf are
very likely to prevent successful utilization of traditional MALDI MS imaging for
characterization of biodistribution of Tf‐based therapeutics in animal tissues.
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Finally, indium labeling provides a possibility to multiplex the measurements,
another very important advantage for both Tf quantitation and imaging studies.
Although in this work all measurements were based on the intensity of 115In, both stable
isotopes of this metal are available commercially, and it is possible to produce and co‐
inject isotope‐coded variants of Tf‐based therapeutics and selectively track them in a
single animal.
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Figure 3‐4 (A) ICP mass spectrum of bovine serum spiked with In2Tf in 150 mM
ammonium acetate (to a total indium concentration of 0.5 ppb). The inset shows a
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zoomed view of the m/z region 104‐126 for the spiked sample (black trace) and the
blank (indium‐free serum sample, gray trace) normalized to the intensity of 120Sn signal.
Colored bars represent natural isotopic distributions of select elements (labeled with
the same color). (B) Calibration curve for indium (115In) in serum obtained with rhodium
as an internal standard. The inset is a zoomed view of the calibration curve below 0.2
ppb of indium.
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Figure 3‐5 LA‐ICP MS imaging of iron (57Fe) and indium (115In) distribution in the cross‐
section of spleen harvested from a rat 24 hours after the injection of In2Tf. Shown on
the left is a photograph of the spleen cross‐section following completion of the imaging
work with laser‐etched lines.
Conclusion
The spectacular progress in the field of ICP MS in the past decade enabled
probing of biometals (such as metals associated with proteins) in biological samples at
unprecedented levels of detail, including sensitive detection and quantitation as well as
spatially resolved measurements (2D‐imaging) in tissues. Tf is a ferroprotein that is used
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as a delivery vehicle in a range of therapies that are currently under development, and
availability of a reliable analytical method to trace exogenous Tf in various biological
samples would be a boon to the drug development efforts. While the cognate metal
(iron) is hardly suitable for the role of Tf tracer due to its high abundance in all living
organisms, it can be replaced with nonferrous metals, some of which can be used as Tf
tracers. Numerous ESI MS‐based methods have been developed in the past two decades
to probe protein/metal complexes at a variety of levels (58,212,216‐220), and many of
these techniques have been used here to investigate three metals (Ni, Ga, and In) as
potential tracers of Tf. One of them (In) has been found to be ideally suited for this role,
as it binds strongly to both lobes of Tf, and allows the latter to retain its receptor‐
binding properties. Absence of strong interferences in ICP mass spectra allows indium to
be detected with high sensitivity in complex biological matrices, enabling both
quantitation of In2Tf in biological fluids and tissue homogenates, and imaging of this
protein in organ cross‐sections. Although this work focuses on intact Tf (rather than
Tf/drug conjugates), a follow‐up paper will present the results of studies of
biodistribution of a Tf‐based antimicrobial agent (a Tf/bacteriolytic enzyme conjugate
(34)) designed to target infections on the central nervous systems that are shielded
from many antibiotics by a blood‐brain barrier.
Further studies will be needed to determine if other nonferrous metals from the
extensive list of Tf binders (204,221) as well as iron isotopes (222‐224) can be used as
tracers of this protein. Expanding the repertoire of Tf tracers will enable multiplexing in
biodistribution studies of exogenous Tf and Tf‐based therapies. Above and beyond Tf,
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the strategy outlined in this work may also be used to facilitate pharmacokinetic and
biodistribution studies of other drug candidates that utilize metalloproteins as vehicles
for targeted delivery (such as the hemoglobin/haptoglobin complex (225)).
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Figure 3‐6 ESI mass spectrum of diferric human transferrin.
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Figure 3‐7 ICP mass spectra of solvents and reagents used in this work for quantitation
of In‐labeled Tf in biological fluids.
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CONCLUSIONS AND FUTURE DIRECTIONS
Mass spectrometry has become a powerful tool in proteomics for the studies of
protein characterization, quantitation, modifications and protein/protein interactions.
MS methods are also being developed to determine both higher order structure and the
dynamics of proteins as well as protein complexes, which successfully complement
other biophysical techniques, such as X‐ray crystallography and NMR spectroscopy. In
this work, we use several MS‐based methods to investigate the biodistribution of Tf and
characterize the molecular mechanism of the Tf/TfR system for the final purpose of
devising highly efficient and selective Tf‐drug delivery systems. The outcome of this
work is:
(i) TfR conformational dynamics and its interactions with different forms of Tf
have been investigated in this work by HDX MS. The functional significance of the
conformational changes in TfR is described as its direct participation in the Tf binding
and internalization and iron release. Analyzing the HDX protection patterns within TfR
using several Tf/TfR models that mimic various stages encountered during endocytosis
reveals a number of unique aspects of the conformational dynamics of TfR in the neutral
and acidic pH that impact Tf binding properties. Binding with holoTf at pH 7.5 induces a
movement at the TfR/TfR dimer interface and stabilizes the apical domain. Decreasing
the pH to 5.5, the pH‐induced conformational changes within the helical domain of TfR
trigger a chain reaction that stabilize the C‐lobe of Tf in an open conformation. The
conformational change at Trp528 in the protease‐like domain influences the position of
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the Tf bridge whereby further accommodates Tf clefts opening. Moreover, site‐specific
interactions of Tf C1/TfR are characterized at both pH 7.5 and 5.5, responsible for its pH‐
dependent Tf binding preference.
The current sequence coverage is about 81% and this number is expected to
increase due to the possibility of identifying the glycopeptides with their characteristic
neutral mass loss (226). In addition, utilizing ion mobility separation which adds a
structure‐based separation to the measurements could also improve the ion signal
sensitivity and enhance peptide ion identification. To further characterize the detailed
site‐specific Tf binding sites on TfR, higher resolution HDX MS/MS measurements with
electron capture dissociation (ECD) or electron transfer dissociation (ETD) fragmentation
using low HD scrambling instrument parameters (227) will be used to study the
conformational dynamics of certain peptides of interest located at the Tf/TfR interface
region at the amino acid resolution level. Obtaining such high spatial resolution
backbone‐amide protection map allows us to better understand the interactions
between Tf/TfR that lead to stabilizing apoTf at acidic condition. Moreover, the
presence of noncanonical states of Tf (211,212) might be also critical to the binding
ability of TfR with apoTf at neutral pH and with holoTf at endosomal pH. This
assumption will be evaluated by characterizing the receptor binding affinity orders of
wild type Tf, Tf variants and non‐canonical states of Tf at both neutral and endosomal
pH levels by direct ESI MS. Although this work is more focused on investigating the
conformation and dynamics of TfR, following experiments need to characterize the
changes on different forms of Tf at neutral and endosomal pH to better understand the
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Tf/TfR binding properties and the roles of iron release in the presence of TfR.
Furthermore, in order to successfully design a rational drug delivery strategy, we need
to further understand the properties of the therapeutic drug‐Tf conjugates and their
interactions with TfR by investigating whether the drug‐Tf would affect the receptor
binding properties and how do Tf and/or TfR modulate the drug in the endosome.
(ii) A new method, using indium as a potential tracer of Tf with ICP MS detection,
is developed to quantitate the exogenous Tf in multiple biological fluids and tissues at
picomol level. With this method, the exogenous Tf has been successfully detected and
quantified in rat CSF after intravenous injection. Moreover, by applying LA‐ICP MS, we
are able to investigate the biodistribution of the exogenous Tf at the cellular level.
However, it should be noticed that the volume of CSF in the rat brain is only
approximately 90 μL (228), and normally the amount of the fluid collected is much less
than this. It is a challenge to collect enough CSF fluid without blood contamination. To
avoid a false‐positive result and confidently investigate the exogenous Tf in rat CSF
rather than from the blood during sample collection process, mercury labeled rat
albumin could be used as an indicator of the contamination of blood in CSF, as the
albumin is only synthesized extrathecally (229). Rat albumin contains one free sulfhydryl
group. Our preliminary study demonstrates that the mercury labeled albumin can be
synthesized using p‐hydroxymercuribenzoic acid (pHMB), a labeling reagent which is
well‐known to form covalent bonds to SH groups of peptide or proteins (Figure 4‐1 and
Figure 4‐2B). By co‐injecting the mercury labeled rat albumin with the indium labeled rat
Tf into the rat, any mercury signal detected by ICP MS in the CSF sample could flag the
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contamination of blood. Furthermore, this method can be further extended to study the
biodistribution of the Tf‐drug conjugates designed to target tumors (17) and CNS
disorders (230). In addition, this method can provide a possibility to enable multiplexing
by utilizing multiple metal ions (204) or isotopes (222‐224) as tracers, so that different
versions of Tf and Tf‐based therapies can be analyzed simultaneously. For example, our
group recently demonstrates the feasibility of using ruthenium as a protein tracer which
can stably bind to the His‐tag segment of a recombinant Tf without interfering the
receptor binding ability (231). When selecting an acceptable Tf tracer, the behavior of
the metal‐Tf complex under conditions mimicking the endosomal environment (where
the release of iron occurs) should be also considered, as the integrity of the complex
should not be compromised (232). Above and beyond Tf, the strategy outlined in this
work may also be applied to investigate the biodistribution of other metalloprotein‐
based drug systems (such as the hemoglobin/haptoglobin complex (233)).
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Figure 4‐1 The mercury labeling strategy is using p‐hydroxymercuribenzoic acid (pHMB)
as a labeling reagent, follows the potential labeling of free sulfhydryl groups derived
from cysteines ubiquitously present in protein.

Figure 4‐2 ESI MS spectra of (A) rat Tf labeling with indium and (B) rat serum albumin
labeling with pHMB. Only protein ion peaks at charge state +20 for indium‐Tf (A) and at
charge state +28 for mercury‐albumin labeling (B) are shown for clarity. Gray trace in
each spectrum shows the reference ion peak of apo‐protein. The theoretical mass
increase of pHMB labeling is 320.7 Da.
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